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                                                         ABSTRACT 
 
OBJECTIVE 
 To   evaluate the efficacy and safety of bromocriptine Quick release QR   
as add on therapy with Metformin and glipizide in type 2DM patients. 
MATERIAL AND METHODS 
 140 patients with Type 2 DM satisfying the inclusion criteria were 
recruited and randomized into two groups. The control group (Group A) was 
treated with Metformin 500mg bd and Glipizide 5mg bd for a period of 3 
months. The study group received Bromocriptine quick release 1.6 mg   once 
daily in the morning in addition to Metformin 500mg bd and Glipizide 5mg bd 
for a period of 3 months. Fasting blood glucose and postprandial blood 
glucose were monitored at 0 month, 1st month, 2nd month and 3rd month in    
both groups. BMI estimation, HbA1C and lipid profile, was done at Baseline 
and at the end of 3 months in both control and study groups. Baseline 
investigations to monitor any change in biochemical and hematological 
parameters were   done before and after drug administration in all patients. 
RESULTS 
 There was significant decrease in fasting blood glucose when compared 
to baseline in both control group [p<0.05] taking metformin and Glipizide 
alone and study group [p<0.05] taking Bromocriptine in addition to metformin 
and glipizide at the end of 3 months. 
viii 
 
 There was significant decrease in postprandial blood glucose when 
compared to baseline in both control group [p<0.05] and study group [p<0.05] 
at the end of 3 months. There was significant decrease in HbA1C when 
compared to baseline in both control group and study group at the end of 3 
months. But the decrease in HbA1C is higher in   the study group [p=0.0001] 
than the control group. [p=0.001]. 
 Also addition of Bromocriptine QR caused significant decrease 
[P<0.05]  of LDL ,TGL and diastolic BP was seen only in study group  not in 
controlgroup. But Total cholesterol, and Systolic BP decreases significantly 
[p<0.05] in both study and control groups.BMI analysis when compared to 
baseline did not show any significant decrease in both control and study 
groups at the end of the study. No serious adverse effects occurred during the 
study period in both study and control groups.  
CONCLUSION 
 In TYPE 2 DM, Bromocriptine QR when combined with metformin 
and Glipizide reduced Fasting blood glucose, postprandial blood glucose and 
HbA1C significantly compared to metformin and glipizide alone.Also, 
Bromocriptine QR when combined with metformin and Glipizide reduced 
LDL, TGL, Total cholesterol and blood pressure significantly compared to 
metformin and glipizide alone.Bromocriptine Quick release is also safe in 
TYPE 2 Dm at doses of 1.6 mg OD. 
KEY WORDS: Bromocriptine, Type 2 Diabetes Mellitus, Metformin, 
Glipizide. 
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INTRODUCTION 
 
 DIABETES MELLITUS [DM] is a chronic disease emerging as a 
global epidemic, alarming people all over the world. It is predicted DM will 
become the 7th leading cause of death in the world by 2020 according to 
WORLD HEALTH ORGANISATION.  INDIA   is described as the diabetic 
capital of the world, because of high prevalence of diabetes in India. Research 
works focusing on prevention and better treatment of DM is absolutely needed 
in our country. Among the various types of DM, Type 2 DM is common 
globally and it is emerging as a key health problem1. 
 DM is a metabolic disorder characterized by chronic hyperglycemia   
occurring as a result of insulin deficiency and insulin resistance.  Treatment 
includes insulin and Oral hypoglycemic agents [OHA].OHA acts by either 
increasing insulin secretion or decreasing insulin resistance or both.  
 Despite the advances in the management of type 2 DM, many patients 
fail to achieve good glycemic control and suffer from complications of DM. 
Even with appropriate dosages of OHA and insulin, not all patients are under 
good glycemic control always. Sulphonylureas can cause weight gain and 
hypoglycemia as side Effects. Insulin secretogogues can cause exhaustion of 
pancreas and decrease in insulin secretion on long term treatment 2. Insulin   
sensitizers alone are not sufficient for achieving normoglycemia in many 
patients. 
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 So there is an absolute need for a continuous search of a novel OHA 
with different mechanism of action and minimal side effects leading to better 
compliance of patients3.Restoration of normoglycemia requires OHA with 
multiple mechanism of action. 
         Bromocriptine Mesylate QR [Quick release] formulation was approved 
by FDA in 2009 for treatment of Type 2 DM 4. It is a unique OHA with 
central mechanism of action resetting hypothalamic circadian rhythm 
.Bromocriptine can be utilized in Diabetes Mellitus as monotheraphy and 
combination therapy5. It improves blood glucose by acting through CNS 
dopaminergic pathways. It addresses the unexplored pathophysiology of DM.  
        The etiology of diabetes mellitus in India is multifactorial and includes 
genetic and environmental factors such as obesity, urban migration, and 
sedentary lifestyle changes. 
        Because of the heterogeneity of culture, living standards and ethnicity in 
the Indian population, regional studies and many nationwide multicenter 
studies are needed. Hence this study was planned to highlight on the 
usefulness of Bromocriptine QR [quick release] as combination therapy along 
with metformin and glipizide in Type 2 diabetes. It was an open label 
randomized controlled study conducted at Chengalpattu Government hospital 
at Tamilnadu.                             
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REVIEW OF LITERATURE 
 
 Diabetes mellitus [DM] is the most common metabolic disorder in the 
world. Increasing prevalence and incidence of DM and increased 
complications of DM have created a compelling need to understand the 
etiopathology and management of DM. 
 History shows there is a continued advance in understanding the 
pathophysiology, diagnosis and treatment of Diabetes mellitus 6 .It also gives 
us a bitter message - despite ever improving treatments, innovative tools, and 
preventive approaches the conflict to protect diabetic population from its grave 
problems is difficult.  
HISTORY7 
o 1921- Banting, Best, Macleod, Toronto Demonstrated   pancreatic 
extracts lower blood sugar in experimental dogs 
o 1922-Leonord Thompson, Toronto first used insulin in humans. 
o 1923-first commercial production of insulin by lily company 
o 1955 -Sanger and coworkers illustrated structure of insulin. 
o 1942-sulphonylureas discovered. 
o 1950-biguanides introduced. 
o 1960-Bersin and Yalow made radioimmunoassay of insulin 
available. 
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o 1964- Gestational DM Diagnosed by O Sullivan and Mahan. 
o 1967-Kelly, Lillie and coworkers made first pancreas transplant. 
o 1971-Roth, Cuatrecasus and coworkers defined insulin receptors. 
o 1977-Ullrich, Rutter, Goodman and others cloned insulin gene. 
o 1981-Kahn and coworkers described insulin receptor kinase 
activity. 
o 1982-Recombinant human insulin came to market. 
o 1989-first islet cell transplant. 
o 1990-insulin pen devices became available. 
o 1995-Metformin became available. 
o 2000- Islet transplantation and EDMONTON PROTOCOL was 
described. 
o 2001- [Insulin Glargine, a long acting insulin analogue] introduced 
by Lantus, Aventis company. 
o 2005-GLP1 ANALOGUES available 
o 2006- FDA approved DPP4 Inhibitors. 
o 2009 –FDA approved use of BROMOCRITINE QR for treatment of 
Type 2 DM. 
o 2013-FDA approved SGLT2 inhibitors.  
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EPIDEMIOLOGY 
WORLD 
 About 285 million people had diabetes worldwide in 2010 of which 
90% had type 2 DM8.Dramatic increase in diabetes  was seen in 2013 to about 
381 million ,as stated by International Diabetes Federation [IDF]. It is 
estimated that the prevalence will almost double by the year 2030.The increase 
in prevalence is expected more in Asian and African countries9.  
 About 21 million pregnant mothers are found to be with gestational 
DM which adds to the universal problem of DM10. 
GROWING PROBLEM OF DIABETES MELLITUS 
 
[Adopted from IDF atlas 2014]  
   American Diabetes association [ADA] states that  By 2030,India will 
have  the highest incidence of Diabetes mellitus 11.  
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NUMBER  OF PEOPLE WITH DM (20-79years), 2013. [Adopted from 
IDF–SIXTH EDITION/11].  
 
       Previously, International Diabetes Foundation stated that India has 
highest Diabetic population than other nations, but now it is depicted that 
China has higher diabetic population than us. According to Indian Heart 
Association, 109 million individuals will be with diabetes by 2035. 
TOP 10 COUNTRIES OF PEOPLE WITH DM 
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    India currently faces an uncertain future due to the potential burden 
imposed by diabetes. Identification of those factors that influences the 
prevalence of disease throughout our country is necessary to face the health 
challenges. Genetic susceptibility, unhealthy diet and sedentary lifestyle by the 
people are mainly the root cause of   high incidence of DM. 
GENETICS 
 In type 1 DM, there is a strong genetic association with HLA-B8-DR3 
and /or DR4 and   recent research shows that when amino acid Aspartate 57 is 
absent in DQB Gene or       when  Arginine 52 is  present in DQA Gene there 
is increase susceptibility to  TYPE 1 DM12 . 
 10% of type 1 DM   patients  are having parent or sibling with the 
disease.  Studies of monozygotic twins show about 30-50% and dizygotic 
twins show 5% concordance of developing the TYPE 1 DM. Population 
studies shows an association between HLA B8 genes DR3-DQ2 and DR4-
DQ813.  
 Type 2 DM is a strong genetic disorder. Studies of identical twins 
reveal 100 % concordance. Its inheritance is complex. Several environmental 
factors particularly   central obesity influences Diabetic genotype. 
 TYPE 2 DM developing below 25 years of age is classified as MODY. 
[Maturity onset diabetes of young].  It is a noninsulin dependent DM. In 
MODY,   onset of DM is early and it   shows autosomal dominant inheritance. 
Mutations in six discrete genes causes MODY. 
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 The causative genes identified in MODY are HNF4Į for (MODY 1)14 
,Glucokinase   for (MODY2),HNF1Į for (MODY3)15,IPF1 for (MODY 4)16 
,HNF I ȕ for (MODY 5)17,18  . 
 In families with later onset   DM , mutations in coding sequence of isle 
1 and neuron D1 was found to bepresent.19 ,20.Mutations in a single 
transcription factor gene  can impair the expression of many islet genes 21 . 
TYPES OF DIABETES MELLITUS: 
x Type   1 diabetesmellitus 
x Type  2   diabetesmellitus 
x Gestational diabetes mellitus 
x Other forms of diabetes. 
o Genetic faults of beta cell dysfunction e.g., MODY 1 to 6 
o Genetic faults in insulin action. 
o Ailments of Exocrine pancreas, e.g., Fibro calculus pancreatopathy 
Diseases of Endocrine system e.g., Acromegaly, Cushing’s, etc. 
o Drugs induced, e.g., glucocorticoids 
o Infections such as congenital rubella 
o  Rarely immune mediated diabetes ,such as Stiff Man Syndrome 
o Other Genetic syndromes 
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TYPES OF DIABETES 
 
Adopted from IDF atlas sixth edition / page no: 12. 
 The American Diabetes Associations [ADA] new classification for 
diabetes is etiologically based, not based on the type of treatment. Type 1 DM 
and Type 2 DM is the preferred nomenclature instead of IDDM and NIDDM. 
Less common types of diabetes include Gestational Diabetes Mellitus and 
Prediabetes. 
TYPE 1 DIABETES MELLITUS 
   Type 1   Diabetes also called as IDDM   is caused by beta-cell damage, 
and absolute insulin   insufficiency. Exogenous insulin doses are needed for 
survival of TYPE 1 DM. Patients, on withdrawal of insulin develops 
hyperglycemia, DKA, coma. Onset of age-usually childhood and adolescence, 
peak at 5 &15 years22 .5- 10% of persons  get  type 1 DM  above 30 years of 
age23 .The etiology of TI DM is beta cell destruction and absolute insulin 
deficiency. Based on this it is further divided in to 2 types 
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x Type 1a:  Autoimmune [islet cell antibody and GAD positive]. 
x Type 1b:  Idiopathic 
x Autoimmune destruction is triggered either  due to viral infection 
such as congenital rubella ,coxsackie virus,mumps,reo virus ,herpes 
virus, echo viruses. or due to environmental factors such as  
x  Increased ingestion of certain medications that may compromise 
pancreas: 
o  Anticancer drugs such as Streptozotocin, 
Hexamethylmelamine and antihistamine   such as 
Cyproheptadine, and rodenticide such as vacor. 
x  Increased free radicals due to changes in environment that damage 
DNA in insulin producing cells. 
ETIOPATHOGENESIS OF TI DM 
Genetic susceptibility 
p 
 
Environmental factors 
p 
 
Immunological activation 
p 
 
Progressive ȕ cell destruction 
p 
Type 1 Dm 
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DIAGNOSIS OF TYPE 1 DM  
 If estimation of glucagon stimulated C-PEPTIDE LEVELS show 
absence or very low levels of C-PEPTIDE, it is diagnostic of TYPE 1 DM. 
These patients have very low ȕ cell reserve.  
TYPE 2 DIABETES MELLITUS 
 Among the diabetic population 95% are of type 2 DM  and only 5% 
suffer from type 1 DM. Usual age of onset is >30 years. But recently obesity 
and occurrence of Type 2 DM in adolescent and childhood age is becoming 
more common.24. 
 Family history is the main risk factor for type 2 diabetes. Progressive 
decrease in secretion of insulin from pancreas and increase in insulin 
resistance leads to type 2 DM.25. 
 Exogenous insulin is usually needed only at times of stress   for 
glycemic control. Insulin Resistance and obesity plays a key role in Type 2 
DM. Liver, skeletal muscle and adipose tissue mainly shows insulin 
resistance. 
Possible causes of INSULIN RESISTACE type 2 Diabetes 
x Decreased insulin receptors on target cells 
x Decreased efficacy of insulin receptors 
x Defect in the post-receptor events. 
x Genetic component 
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OTHER WARNING   FACTORS FOR TYPE 2 DIABETES  
 Family history, Increasing age, central obesity, and sedentary lifestyle. 
ETIOPATHOLOGY OF TYPE2 DM: 
Genes , Obesity, Ǻ Cell Capacity, Insulin Resistance 
p 
Environment, Abundant Food, Less Physical Activity 
 p 
 Insulin Resistance, Hyperinsulinemia [ȕcellcompensation] 
 p 
 Ǻ Cell Decompensation, IGT 
 p 
 Declineof ȕ cellmass,Severe Hyperglycemia, Hypoinsulinemia, 
Glucotoxity,Type 2dm 
OBESITY AND TYPE2 DIABETES MELLITUS 
  
  One of the important risk factor for type 2 DM is obesity.
Obesity aggravates type 2 diabetes. 
13 
 
  As body fat increases, insulin resistance increases due to decrease in 
insulin receptor number and decline in receptor function. Type 2 diabetes and 
obesity becomes a viscous cycle. Therefore obese individuals need extra 
insulin than non-obese individuals to preserve normal blood glucose. 
CLINICAL SYMPTOMS OF TYPE 2 DIABETESMELLITUS: 
 Type 2 diabetes usually present with less dramatic symptoms than that 
of type 1.Many type 2 diabetics are undiagnosed. They come with nonspecific 
symptoms of their complication and identified with hyperglycemia. Symptoms 
of Type 2 Diabetes are 
x polyuria, polydipsia ,polyphagia 
x Blurred vision 
x Pruritus vulvae  
x Skin infections  
GESTATIONAL DIABETESMELLITUS  
 When glucose intolerance develops or when it is recognized in 
pregnancy it is defined as gestational diabetes mellitus. It usually reverts back 
to normal in the postpartum period. In future they have increased risk of 
evolving   into Type 2 DM. Periodic monitoring thereafter is needed for them. 
Screening for and diagnosis of GDM 
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 Diagnosis of GDM is by glucose tolerance test .OGTT to be done at 24-
28 weeks of pregnancy. After parturition, OGTT  is to be done after 6 weeks, 
after 6 months and then yearly checkups needed. 
 
DIAGNOSIS OF DM   
 Diagnostic characteristic for diabetes mellitus is hyperglycemia.  Stress 
and medications can cause hyperglycemia as a side effect. Hence proper 
diagnoses of DM are essential.  
ADA CRITERIA FOR THE DIAGNOSIS OF DIABETES26  
x A1C >6.5%. 
x FASTING PLASMA GLUCOSE   > 126 mg/dL or (7.0 mmol/L). * 
x  POSTPRANDIALPLASMA GLUCOSE >200mg/dL or (11.1mmol/L)  
x OR 
x Hyperglycemic symptoms/ crisis with a Random Plasma Glucose>200 
mg/dL or (11.1 mmol/L) 
Rationale for the diagnostic criteria: 
x  FBG and 2-h BG levels are proportional to risk of micro vascular and 
macro vascular disease. 
x FBG is simpler and cheaper test than OGTT. 
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CARPENTER   AND COUSTAN CRITERIA FOR DIAGNOSIS OF 
GESTATIONAL DIABETES MELLITUS 
100g   OGTT 
x Fasting: >95 mg/dl  (5.3 mmol/L) 
x 1 h: >180 mg/dL  (10.0 mmol/L) 
x 2 h: >155 mg/dL  (8.6 mmol/L) 
x 3 h:>140 mg/dl(7.8 mmol/l)  
75 g OGTT 
x Fasting: >95 mg/dl  (5.3 mmol/L) 
x 1 h: >180 mg/dL  (10.0 mmol/L) 
x 2 h: >155 mg/dL  (8.6 mmol/L) 
PREDIABETES: 
¾ A1C 5.7–6.4% 
¾ FPG   100 TO 125 mg/dl is said to be impaired fasting glucose; 
¾ PPBG 140 TO 199mg/dl is said to be impaired glucose tolerance. 
COMPLICATIONS OF DM: 
  The metabolic derangement in DM leads to secondary pathophysiologic 
changes affecting multiple organs and imposes a   problem not only on the 
individual with diabetes but also on the health care system27. 
Complications of DM can be acute or chronic. 
Acute Complication 
16 
 
 Results  from acute changes in blood glucose. 
x Diabetic ketoacidocis,  
x Hyperglycemic hyperosmolar syndrome (hhs), 
x hypoglycemia. 
 
 
Chronic (long-term) complications: 
Microvascular complications 
 Retinopathy (nonproliferative/proliferative) 
 Neuropathy 
 Peripheral neuropathy/ 
 Autonomic neuropathy 
 Nephropathy 
Macrovascular Complications: 
x Coronary artery disease 
x Cerebrovascular disease 
x Peripheral vascular disease 
Additional complications 
x (Gastro paresis, loose stools) 
x (uropathy/erectile dysfunction) 
x Skin diseases 
x Infections 
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x Cataracts 
x Glaucoma 
x Periodontal disease  
x Hearing defects 
  
 
 
MAJOR COMPLICATIONS OF DIABETES MELLITUS 
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ACUTE COMPLICATIONS  
Hypoglycemia  
 It is the most frequent and dangerous acute complication usually 
resulting from insulin therapy28, 29. Inappropriate timing of food, exercise, 
and insulin treatment can lead to hypoglycemia30.  
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HYPOGLYCEMIA 
 
Symptoms of hypoglycemia include: 
¾  Symptoms of sympathetic activation: 
 Pallor, tremor, palpitations, anxiety, hunger, vomiting, fever, moderate 
tachycardia, systolic hypertension. 
¾  Symptoms of parasympathetic activation: 
 Nausea, eructation, sweating, bradycardia, hypotension. 
¾  Signs and symptoms of neuroglycopenia: 
 Headache, dizziness, fatigue, irritability, perioral numbness, disturbed 
vision, paresthesia, confusion, cognitive impairment, psychotic behavior, 
Occasionally focal neurological defects, hemiparesis, convulsions, coma 
death. Hypoglycemic unawareness is mostly seen in chronic diabetes. It warns 
for regular and periodic monitoring of blood glucose in them. 
HYPERGLYCEMIA  
 High blood glucose by osmosis causes intracellular and extracellular 
fluid depletion and dehydration.   It also results in excessive urination and thus 
dehydration. 
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HYPERGLYCEMIA 
  
Symptoms of hyperglycemia include: 
x Polydipsia and polyuria 
x increased hunger 
x loss of Weight 
x Unclear vision. 
x breath smells of acetone (due to ketosis) 
x Glycosuria 
x Labored breathing  
x Coma (from ketoacidosis  commonly seen in type 1 diabetics) 
x Hyperosmolar hyperglycemic non ketotic coma ( in  type 2 
diabetics) 
x Death 
Amplified mortality in DM is produced   by DKA and HHS. 
DIABETIC KETOACIDOSIS   
Type 1 DM usually exhibits DKA as its common complication .But at 
times of catabolic stress, Type 2DM also presents with DKA31. Hyperglycemia 
and increased circulating total body ketone levels causes  metabolic acidosis. 
When there is shortage of insulin and simultaneous raise of counter regulatory 
hormones ketoacidosis occurs32,33. This hormonal imbalance leads to increased 
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lipolysis and ketosis .Ultimately this acidic ketones lead to DKA and its 
manifestations. 
LIPOLYSIS AND KETOSIS. 
 
CRITERIA FOR   DIAGNOSIS OF DKA: 
 Blood glucose level more than 250 mg/dl, presence of ketonemia or 
ketonuria, serum bicarbonate lessthan15 me/l, pH less than 7.3 in ABG, 
[metabolic acidosis] 34. 
Treatment of DKA includes fluid therapy, insulin therapy, potassium, and 
bicarbonate and phosphate correction34. 
HYPERGLYCEMIC HYPEROSMOLAR SYNDROME (HHS): 
 HHS is common in type 2 diabetes. About 7–17% of diabetic patients 
manifest HHS as their first manifestation of DM35.  The major precipitating 
factors are infections, especially   UTI and pneumonia, cerebrovascular   
disease or myocardial infarction.35 Treatment of HHS in general includes 
systematic monitoring of blood glucose, rectification of hypervolemia   and 
electrolyte losses, and treatment of precipitating causes in addition to insulin 
therapy. 
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CHRONIC COMPLICATIONS: 
 Retinopathy, neuropathy and nephropathy are the chronic 
complications of DM. The UKPDS Study demonstrated that, in type 2 DM 
decrease in mean HbA1C, seen in intensive therapy [7.9%] is more when 
compared to conventional therapy [7.0%] 36. It also states that overall 25% 
decrease in rate of micro vascular complications is caused by intensive 
treatment in type 2 DM36 
 END STAGE RENAL DISEASE is commonly due to DM. About 
40% of   Type 1 diabetic patients suffer from severe kidney disease   above 50 
years of age.  
NEPHROPATHY  
 Diabetes is the most common cause of ESRD, resulting in about one-
third of new ESRD patients every year. Nearly 40% of people with type 1 
diabetes develop severe kidney disease and ESRD by the age of 50. 
KIDNEY DAMAGED BY DIABETES 
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 The kidney disease progresses to ESRD in about 17 years in Type 1 
DM. Hypertension and atherosclerosis affects kidney vessels and contribute to 
nephropathy. Micro proteinuria is an initial manifestation of kidney damage. 
Progression of nephropathy can be slowed by  Angiotensin-converting enzyme 
(ACE) inhibitors  and Calcium channel blockers .Low protein diet   are also 
found to be useful. Intensive treatment of hyperglycemia caused a 50% 
reduction in both incidence and progression of nephropathy according to the 
DCCT.  
RETINOPATHY 
 Poor glycemic control increases the risk of retinopathy. Several studies   
identify hyperglycemia, high blood pressure and hypercholesterolemia as risk 
factors for Diabetic retinopathy37, 38.39,40,41... Decrease of HbA1c to 7%, 
decreased development and advancement of Diabetic Retinopathy   in diabetes 
mellitus patients 42, 43, 44.  
 The DCCT study also detected that intensive treatment of DM 
minimized the risk of retinopathy by 76%.Intensive control of blood glucose 
in early stages of diabetic retinopathy decelerated the progression of eye 
damage by 50%. 
DIABETIC NEUROPATHY 
 Hyperglycemia is highly linked with the occurrence and progression of 
all neuropathies, comprising Peripheral diabetic neuropathy [PDN].45, 46. The 
Diabetes Control and Complications Trial (DCCT) established that the 
incidence of neuropathy will be decreased by 60% as the result of tight 
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glycemic control47.  But the incidence of neuropathy remains 20%, even after 
good glycemic control48. Significant nerve damage can be decreased by 60% if 
blood glucose is strictly controlled as stated by DCCT. 
Types of neuropathy include 
x Peripheral neuropathy 
x Mononeuropathy 
x Autonomic neuropathy 
CARDIOVASCULAR DISEASE AND STROKE 
 Diabetic Patients are under high risk of succumbing to cardiovascular 
disease (CVD) and stroke. The increased morbidity and mortality in diabetes 
patients is mainly attributed to CVD49. Congestive cardiac failure is 
increasingly seen in DM. 
   Hyperglycemia leads to glycosylation of proteins including LDL 
Apo proteins. Hyperinsulinemia has also been implicated as cause of 
atherosclerosis leading to CVD and stroke. Elevated cholesterol values are 
seen more in Diabetics than Nondiabetics50, 51. Other risk factors of type 2 DM 
are commonly present, such as hypertension, obesity, lack of exercise, age, 
and smoking. 
MANAGEMENT OF DIABETES MELLITUS 
 Diabetes management is an ongoing and continuous process. To ensure 
the best possible outcomes, it should   involve diet, exercise, medication, and 
monitoring.  
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 The American Dietetic Association   recommends medical nutrition 
therapy for diabetic patients as follows 
x Maintain a balance between food /insulin / oral glucose lowering 
medications and   exercise levels. 
x Maintain normal  serum lipid levels 
x Provision of adequate calories for maintaining  normal weights 
for adults, normal growth in children and adolescents,  and for 
meeting the metabolic needs  of pregnancy ,lactation, and  
catabolic illnesses 
x Prevention and management of the complications of DM. 
 The cornerstone in diabetic management is diet and exercise. The 
dietary management should be aimed at and achieving maintaining ideal body 
weight, normal lipid profile and euglycemia.Diet should be individualized 
considering ethnic, cultural issues and comorbid conditions.   
TOTAL CALORIES DISTRIBUTION  
 [ICMR Guidelines –nonpharmological management of DM] 
 Carbohydrates should be 55-60% of total requirement: 
 The main source should be cereals, pulses, grains, soyabeans.It is 
advised that roots and tubers to be used sparingly. Use of honey, sugar, 
sweeteners and Maida products to be avoided. 
26 
 
Proteins should be 10-15% of total requirement.  
 It should be from vegetables, fish, lean meat and low fat milk and milk 
products. 
Fat should be 20-25% of total requirement 
 Less than 7% should be   saturated fat; the remaining should be MUFA 
and PUFA. Dietary cholesterol should not exceed 300mg/day. Ricebran 
oil,groundnut oil ,sesame oil   have linoleic acid n-6 and oil containing Į 
linoleic acid such as mustard oil,soyabean etc to be used. Diet rich in fruits 
and fiber to be advised.common salt intake  less than 6g% to be  advised. 
Alcohol aggrevates obesity,dyslipidemia and neuropathy.so it should be 
avoided,or to be taken only moderately.use of tobaco and smoking to be 
prohibited. 
Exercise/ Activity 
 Effect of exercise revealed beneficial results for T2DM deprived of any 
adverse effects. The benefits of exercise such as reduction of bodyweight are 
of greater utility in obese patients with diabetes mellitus52, 53. 
  In the skeletal muscle increased glucose uptake via glucose transporter 
4 (GLUT4) during the exercise causes decrease in the blood sugar level in 
T2DM patients 54. 30 to 45 min of aerobic exercise, 3 to 5 days in a week 
(minimum of 150 min/week) is advisable. Walking 1 hour/day or jogging 30 
min/day will lead to decrease in body weight on longterm.55. 
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MONITORING OF DIABETIC PATIENTS: 
 Glycemic control over the past 2-4 months can be picked up by 
Glycosylated hemoglobin, (HbA1c). Normal range of DM is 4-6% 
Glycosylated Haemoglobin 
 
x  Periodic Ophthalmic evaluation and renal and cardiac status evaluation 
is essential. 
DRUG THERAPY TO DM  
1. Insulin Therapy 
2. Oral antidiabetic medications 
INSULIN THERAPY. 
 Type 1 diabetics need insulin therapy for survival, and many type 2 
diabetics need insulin therapy for glycemic control .Source of exogenous 
insulin is used   and human insulin has been available since 1980. Insulin used 
now days is prepared by recombinant DNA technology. There are 3 types of 
insulin   based on their duration of action as shown below. 
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 PROPERTIES OF INSULIN INJECTIONS 
Properties of Insulin Injections Action time-hours 
Preparation Onset, Peak, Duration, 
Short-acting    
  As part <0.25 0.5–1.5 3–4 
  Glulisine  <0.25 0.5–1.5 3–4 
  Lispro <0.25 0.5–1.5 3–4 
  Regular 0.5–1.0 2–3 4–6 
Long-acting    
  Detemir 1–4 —a 24 
  Glargine 1–4 —a 24 
  NPH 1–4 6–10 10–16 
Combinations of Insulin    
  [75/25] 75% protamine Lispro, 25% Lispro <0.25 1.5 h 10–16 
[ 70/30]70% protamine Aspart, 30% as Aspart <0.25 1.5 h 10–16 
  [50/50] 50% protamine Lispro, 50% Lispro <0.25 1.5 h 10–16 
  [70/30] 70% NPH, 30% regular 0.5–1 Dual 10–16 
 
Adopted from   Harrison’s textbook of medicine  
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DURATION OF ACTION OF HUMAN INSULIN 
 
 Insulin injection regimen should mimic the body's physiological insulin 
pattern as much as possible. Rapid acting insulin controls of meal surges; long 
acting mimics the baseline secretion. Ultra-rapid acting insulin can be injected 
just prior to ingesting an unplanned food.. Insulin is injected 2-3 times a day, 
as a mixture of long and intermediate or rapid acting insulins. Usual dosage of 
insulin   is 0.5 to 1 unit of insulin per kg body weight insulin dosage needs to 
be   decreased with exercise and increased with stress (pregnancy, surgery, 
illness). 
 Insulin pumps are used by some diabetics allows greater flexibility in 
diet and tight control of blood glucose. The continuous subcutaneous insulin 
infusion (CSII) system consists of a preprogrammed pump. It provides insulin 
at a basal quantity between meals and more   bolus of insulin at meal times. 
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 ANTIDIABETIC DRUGS 
 ORAL HYPOGLYCEMIC DRUGS  
 Sulphonylureas;  Meglitinides. 
 ANTIHYPERGLYCEMIC AGENTS 
 Metformin, 
 Thiazolidinediones 
 ǹ Glucosidase Inhibitors, 
 DPP 4 inhibitors, 
 Incretin Mimetics, 
 Amylin receptor agonists.      
PRIMARY ACTIONS OF ANTIDIABETIC DRUGS 
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1.  SULPHONYLUREAS 
Mechanism of action:  it increases insulin secretion. 
HbA1c reduction: 1-2% 
Advantages: inexpensive 
Adverse effects: weight gain and   hypoglycemia 
Contraindications:  kidney and liver disease. 
2. MEGLITINIDE ANALOGUES: 
Mechanism of action:  it increases insulin secretion. 
Advantages: Quick and short acting. Decreases PPBS.Nateglinide can 
be used in patients with liver dysfunction. 
Adverse effects: hypoglycemia. [If meal is skipped] 
Contraindications:  liver diseases. 
3.  BIGUANIDES: METFORMIN 
Mechanism of action: it decreases hepatic output of glucose. 
HbA1c reduction: 1-2% reduction is seen with metformin. 
Advantages: it is weight neutral, it does not cause hypoglycemia. 
Adverse effects: nausea, diarrhea and other GI side effects, lactic 
acidosis rarely. 
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4 . THIAZOLEDINEDIONES: 
Pioglitazone 
Mechanism of action:  decreases insulin resistance by PPAR – Ȗ 
agonistic action. 
HbA1c reduction: 0.5-1.4% 
Advantages: it decreases insulin resistance and increases peripheral 
glucose uptake. 
Adverse effects: peripheral edema, CHF, weight gain, fractures, 
macular edema. 
Contraindications: CHF, liver disease. 
Rosiglitazone has been withdrawn from market because it causes 
increased CVS risk.  
5.  BILEACID SEQUESTRANTS: 
COLESEVALAM 
Mechanism of action:  
It binds bile acids and it decreases blood glucose by unknown 
mechanism 
HbA1c reduction: 0.5% reduction is seen. 
Adverse effects: constipation, dyspepsia, abdominal pain, nausea, 
intestinal obstruction.it also interferes with absorption of other drugs. 
Contraindications: elevated plasma triglycerides. 
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6.  GLUCOSIDASE INHIBITORS 
Acarbose, miglitol. 
Mechanism of action:  it decreases intestinal glucose absorption 
HbA1c reduction: 0.5-0.8% 
Advantages: Decreases PPBS 
Adverse effects: gastrointestinal adverse effects, flatulence, abnormal 
liver function tests. 
Contraindications:  kidney and liver disease 
7.  DPP 4 Inhibitors 
Saxagliptin, sitagliptin, vildagliptin. 
Mechanism of action:  it prolongs endogenous GLP 1 action which 
stimulates insulin secretion. 
HbA1c reduction: 0.5-0.8% 
Advantages: hypoglycemia does not occur. 
Contraindications: renal disease needs reduction of dose.  
8.  GLP 1 RECEPTOR AGONISTS 
Eventide, liraglutide. 
Mechanism of action:  it increases insulin secretion, decreases glucagon 
secretion, slows gastric emptying, satiety. 
HbA1c reduction: 0.5-0.1% 
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Advantages: causes weight loss, do not cause hypoglycemia. 
Adverse effects: given as SC injection; hypoglycemia when given with 
insulin secretogogues, pancreatitis, Kidney failure. 
Contraindications: 
            Renal disorder, drugs that decrease GI motility. 
DESCRIPTION OF DRUGS USED IN STUDY 
x Metformin 
x Glipizide 
x Bromocriptine 
METFORMIN 
 It is an insulin sensitizer belonging to biguanides group.it has direct 
anti-hyperglycemic action. 
 It is the first line drug in obese type 2 DM. 
MECHANISM OF ACTION 
 It reduces hepatic glucose output and it augments glucose utilization by 
muscles .It also decreases FFA availability by inhibiting lipolysis. 
 At cellular level, it increases insulin sensitivity 
x By increasing insulin binding,  
x Stimulating insulin receptor tyrosinase kinase activity 
x Enhanced glucose transport [GLUT 4] 
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x Increases glycogen synthase. 
x In addition, it also has anorexogenic effect, and it also inhibits 
intestinal absorption of glucose. 
x Advantage over sulphonylureas: 
x It is only antihyperglycemicagent but not hypoglycemic agent 
x DOSAGE: available as 250 mg, 500mg, and 850mg tablet 500mg and 
1 g SR tablets also available. 
THERAPEUTIC USES 
x Obese type 2dm, 
x Secondary failure to sulphonylureas 
x Brittle diabetes 
x In insulin resistance to decrease insulin requirements 
x PCOD 
x Non Alcohic Steatohepatitis [NASH]. 
SIDE EFFECTS 
 Gastrointestinal Effects -20% experience anorexia, nausea, 
vomiting and diarrhea, B12 malabsorption in 2000mg or 
more. 
 Lactic Acidosis 
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Contraindications 
x Impaired renal function [serum creatinine  1.5mg/dl in man,  
1.4mg/dl I women; GFR <70 ml/min.] 
x symptomatic CHF requiring pharmacologic treatment 
x chronic liver disease 
x elderly 
x pregnancy 
x lactation 
x type 1 DM 
x patients with alcohol dependence 
GLIPIZIDE 
  Is an insulin secretogogues, belonging to second generation 
sulphonylureas. 
Mechanism of action 
 Competitively blocks the sulphonyl urea receptors on the beta cells of 
pancreas 
ATP sensitive K channels is blocked 
p 
Depolarization 
p 
CA 2+ entry 
p 
Insulin secretion. 
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 It lowers postprandial blood glucose by causing increased insulin 
release.  It also has extra pancreatic effect of increased insulin sensitivity by 
increase in receptor numbers and post receptor effect56.  
PHARMACOKINETICS 
 Dosage-2.5-40 mg/day 
 Duration of action of effect: 12-24hours; halflife 1-4 hours; available as 
5mg tablet  Can  be given OD or BD. Glipizide is absorbed rapidly and has 
short duration of action. 
ADVERSE EFFECTS  
 Gastrointestinal side effects [nausea, vomiting, heartburn, hepatitis and 
cholestasis] skin rashes, blood dyscrasias common to all sulphonyl ureas 
Contraindications 
x Type 1 DM 
x Pregnancy 
x Allergy To Sulphonyl Ureas 
x Liver And Kidney failure 
x Surgery And Postoperative period 
x Severe Infections 
BROMOCRIPTINE 
 Bromocriptine is a dopamine   D2 receptor agonist   acting centrally. . It 
has a strong agonistic action on dopamine D2-receptor .It inhibits pituitary 
secretion of PRL[prolactin]. Bromocriptine also possesses partial D1-receptor 
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agonist activity, 5-HT2 antagonist effects and mild adrenergic effects.57. 
Chemistry: it is a tetracyclic ergo line compound derived from plant alkaloids. 
MOLECULAR STRUCTURE OF BROMOCRIPTINE QUICK 
RELEASE. 
 
Pharmacokinetics 
 Dosages: Bromocriptine quick release is administered once daily and 
within 2 hours of awakening. The recommended initial dose is 0.8 mg daily, 
increased by 0.8 mg weekly (1.6 - 4.8 mg). It   is to be managed as a only 
daily dose within two hours of awakening in the morning and preferably with 
diet to minimize nausea... When administered orally, about 65-95% is 
absorbed within 30 minutes. 
  The peak plasma concentration is reached in about 53-60 minutes if the 
patient is on an empty stomach... The absorption is delayed by the food.  Due 
to an extensive first-pass effect in the liver bioavailability is only 7 %. 
  In other indications 5.0–7.5 mg/day causes marked fall in the 
concentration of circulating prolactin. Higher doses are needed to treat 
acromegaly and Parkinsonism. Bromocriptine is metabolized in liver by 
cytochrome P 450[CYP3A4], and approximately 16-30 metabolites are 
39 
 
formed. The biologic activity of these metabolites is not known. The main 
route of excretion is biliary route; 2-6% is excreted via the kidneys 
approximately. Common side effects include nausea, headache, vomiting 
dizziness and fatigue58.. These side effects occur mainly during the initial 
titration phase and are transient, lasting around 14 days. 
 It can cause syncope and orthostatic hypotension in patients taking 
antihypertensive patients. [Especially on initiation and dose escalation]. 
Bromocriptine inhibits lactation in nursing women. 
CONTRANDICATIONS: 
x Type1 DM 
x Syncopal attacks 
x psychosis 
x hypersensitivity to ergot-related drugs/Bromocriptine 
DRUG INTERACTIONS 
 since Bromocriptine is  chiefly metabolized by CYPA4 enzyme 
pathway, 
 CYPA4 inducers decrease the plasma level of Bromocriptine 
and CYP3A4 inhibitors increases the plasma concentration of 
Bromocriptine. 
 Bromocriptine Mesylate –highly protein bound; can displace 
other protein bound drugs such that salicylates, sulfonamides, 
chloramphenicol, probenacid and so alter their action. 
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 Dopaminereceptorantagonists:-antipsychotics [phenothiazine, 
thioxanthenes butyrophenones] and metoclopramide decrease 
the efficacy of Bromocriptine and vice versa. 
 When used with ergot associated drugs, it increases side effects 
of ergot drugs, so not to use ergot agents within six hours of 
Bromocriptine intake. 
MECHANISM OF ACTION OF BROMOCRIPTINE 
  It has a unique mechanism of action   that decreases plasma glucose, 
triglycerides, FFA levels, and thus decreases cardiovascular risk.  The benefit 
of Bromocriptine in diabetes mellitus is through modulating central glucose 
and energy metabolism pathways59, 60. 
 It can be used as monotheraphy or as combination therapy to 
antidiabetic medications like metformin/sulfonylurea. It is not recommended 
for the treatment of type-1 diabetes or diabetic ketoacidosis. Bromocriptine is 
administered within two hours of awakening as a quick release formulation.  It 
augments   the hypothalamic dopamine levels which are low in DM and 
prevent undue sympathetic tone in the central nervous system, thus suppresses 
of hepatic glucose synthesis. As a consequence there is reduction in post meal 
plasma glucose61. 
  
41 
 
BROMOCRIPTINE QR –MECHANISM OF ACTION. 
 
 Bromocriptine Improves dopamine, which has a role in controlling 
metabolic effects. Drugs with antidopemenirgic effects like antipsychotic 
drugs show negative effects like increased insulin resistance, dyslipidemia and 
weight gain. 
CENTRAL MECHANISM OF ACTION OF BROMOCRIPTINE. 
 
 Bromocriptine with dopaminergic effects show good metabolic profile, 
by decreasing blood glucose, dyslipidemia, and causing weight loss. 
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GLUCOSE HOMEOSTASIS AND INSULIN SENSITIVITY.  
 
MIGRATING BIRDS & THRIFTY GENE HYPOTHESIS 
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 The hypothesis behind obesity and insulin resistance is the thrifty gene 
hypothesis that is insulin resistance is an adaptive state of many vertebrate 
species in preparation for periods of hibernation, winter and famine.63 During 
Evolution in animals, an increased body weight and insulin resistance was 
needed as protective during winter months or times of famine. The insulin 
resistant state ensures glucose supply to the central nervous system by 
increasing hepatic glucose output and by decreasing peripheral glucose 
utilization .it also raises lipolytic action for peripheral use. 
 Animals  then revert back to an insulin sensitive condition when there 
is abundance of food. These changes in body weight and insulin resistance 
depending on season are due to changes in hypothalamic neuroendocrine 
rhythms 64.The serotonin and noradrenalin levels in the ventromedial 
hypothalamus are increased when there is the insulin resistant state. 
Bromocriptine   reduces noradrenergic as well as serotonergic activity on 
ventromedial hypothalamus and reverses the insulin resistant   state when 
given systemic or intracerebroventricular route in animals. 
 In humans, similar change in these neuroendocrine rhythms results in 
the non-seasonal development of obesity. The metabolic modifications such as 
insulin resistance, increased hepatic glucose output and increased lipolysis) 
which are needed in times of fasting or famine  occurs  in other period also .As 
a consequence there is an  increased blood sugar and dyslipidemia in type 2 
diabetic patients. 
 
44 
 
Reason for giving Bromocriptine in the morning: 
 In Type 2 diabetes mellitus patients the dopamine levels are lower in 
the morning when matched to nondiabetic population, leading to augmented 
sympathetic activity. The Bromocriptine quick release variant is usually given 
in the morning to reimburse for morning dip of dopamine. This Bromocriptine 
given in the morning augments this low hypothalamic dopamine levels and 
thereby inhibits the excessive sympathetic activity within the central nervous 
system. 
  Studies also shows Bromocriptine causes decrease in BP and decrease 
in adverse cardiovascular events. In some studies the results show 
insignificant effect of Bromocriptine on weight, however in all studies 
Bromocriptine does not cause weight gain64. Bromocriptine (Ergo set) reduces 
body weight. By the chronological interaction with circadian oscillations of 
neuroendocrine system, Bromocriptine modifies neurotransmitter action in the 
brain and improves glycemic control and insulin resistance in animal models 
of obesity and diabetes.65.  
 Hence by all these mechanisms Bromocriptine reduces blood sugar of 
studies support inhibitory effects of dopamine on insulin secretion [by 
Bromocriptine s agonist action on dopamine receptor. 
BENEFITS OF BROMOCRIPTINE 
 Bromocriptine is a well-known drug for the treatment of Parkinson’s 
disease, hyperprolactinemia or acromegaly.  In 2009   Bromocriptine quick 
release variant was approved in the USA for the treatment of type 2 diabetes 
mellitus. Bromocriptine induces positive metabolic effects such as decreasing 
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blood glucose and serum lipid profile and positive effect on body weight, 
blood pressure and cardiovascular events. The benefits of Bromocriptine are 
of greater utility in obese type 2 DM. The peculiar advantage of 
Bromocriptine is that it does not causes hypoglycemia. 
 Being a dopamine receptor (D2) agonist, it can reduce sympathetic 
activity and circulating NE levels. Thus it helps in the management of high 
blood pressure and LVH in patients with CKD. some research studies 
establishes that the  low dose Bromocriptine  causes blood pressure control 
and reduces LV mass in both peritoneal dialysis and hemodialysis patients and 
thus shows cardio protective effects66. 
 In addition, BEC also has metabolic effects, reducing insulin resistance 
and improving glycemic control in overweight and patients with T2DM. 
Quick-release BEC was approved by the US Foodland Drug Administration 
for the management of T2DM 67, 68, 69.  Several studies demonstrated the 
beneficial effects of Bromocriptine on psoriatic skin lesions, psoriatic arthritis, 
and autoimmune diseases such as systemic lupus erythematous, rheumatoid 
arthritis, Reiter’s syndrome and uveitis.70, 71, 72. 
 Several randomized controlled trials (mostly combining Bromocriptine 
with other oral glucose lowering medication) show a significant reduction in 
several metabolic parameters such as a 0.4-0.7% reduction in HbA1c73 
 Bromocriptine apart from improving glycemic control it reduced body 
fat stores, thus diminishing the need for oral hypoglycemic agents in obese 
type 2 diabetic patients. 74. 
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AIMS AND OBJECTIVES 
Aim 
   To evaluate   the   efficacy and safety of Bromocriptine in Type 
2 Diabetes Mellitus. 
 Objectives 
 Primary objective: 
         To assess the efficacy of Bromocriptine as an add on therapy in 
lowering the Blood sugar level in known Type 2DM patients taking metformin 
and glipizide with poor glycemic control. 
 Secondary objective 
        To evaluate the safety of Bromocriptine as add on therapy with 
metformin & glipizide in T2DM patients with poor glycemic control. 
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MATERIALS AND METHODS 
 
STUDY DESIGN:  
 A prospective, open labeled, comparative, randomized controlled study. 
STUDY CENTER:   
 Department of General medicine – Diabetic OPD .Government   
Chengalpattu medical college and Hospital, Chengalpattu.      
DURATION OF THE STUDY: one year  
2014-2015. 
PERIOD OF STUDY   
 3 months per patient. 
STUDY POPULATION 
          Patients with Type 2DM attending diabetic OPD. 
SAMPLE SIZE 
          60 patients in each group. 
SELECTION CRITERIA 
Inclusion criteria 
x Known T2DM for more than 5 years patients with Fasting blood sugar 
more than 126mg% and post prandial blood sugar  more than 200mg%  
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x  Known T2DM for more than 5 years taking metformin 500mg bd and 
glipizide 5mg bd 
x Sex: both male and female patients. 
x Age 30-60 years 
x Patients who are willing to give informed consent. 
Exclusion criteria   
x All cases of Type 1DM 
x Pregnant & lactating women 
x Age < 30 years and >60 years of old. 
x patients with FBS>300mg/dl AND PPBS> 400 mg/dl and HbA1C 
>10% 
x Patients in whom insulin is indicated for treatment 
x Patients associated with renal & liver disease 
x Patients with coronary arterial disease, CCF, migraine, PVD 
x Patients with known hypertension > 140/90mmhg  
x Any concurrent intake of sympathomimetic drugs 
x Any other serious medical or surgical illness. 
STUDY PROCEDURE: 
Ethical consideration: 
x This study was conducted after getting approval of institutional ethical         
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committee. The study   was conducted as per GCP guidelines. 
x  200 Adult Type 2 DM patients fulfilling the inclusion criteria were 
included in the study. Patients attending the OPD of diabetology 
department, Chengalpattu medical college hospital were explained in 
detail about the study procedure, purpose, benefit & possible risks in 
regional language. 
x Written informed consent got from the patients who were willing to 
participate in the study. Patient information sheet and consent form 
were in regional language {Tamil} and also in English for people who 
know only English. Patients who were illiterate were explained about 
the study and left thumb impression obtained from them in the presence 
of impartial witness. 
SCREENING 
 After getting informed consent, 200 patients with type 2DM, 
FBS[>126mg% and PPBS> 200 mg%] and already on  metformin 500mg bd 
& Glipizide 5mg bd were screened as follows. Detailed clinical history and 
demographic particulars were collected from all patients. 
x Age, Gender, Bodymassindex, clinical examination details were 
recorded for each patient. 
x  Baseline investigations, Hemoglobin, total count, differential count, 
Erythrocyte Sedimentation Rate (ESR), LFT, Blood urea, serum 
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creatinine, blood lipid profile, urine routine were done and recorded for 
each patient. Chest XRAY, ECG was taken for each patient. 
Recruitment & Randomization  
 After screening 200 patients, 130 who fulfilled the selection criteria 
were recruited for the study. 
  All the odd number patients were allocated into control group and all 
the even number of patients were allocated into study Group. 
  All the patients were advised   to follow the diet chart and 30-45 
minutes of moderate   aerobic activities 3-5 days per week. 
Study Group 
 Patients already on metformin 500mg bd & Glipizide 5mg bd were 
added Bromocriptine 1.6mg od for a period of 12 weeks. 
Bromocriptine Priscription75 
 Daily morning Bromocriptine 0.8 mg OD within 2 hrs of waking ,for 
initial 1 week, followed by single morning dose of 1.6 mg/day within 2hrs of 
awaking for   next 11 weeks was prescribed. 
Control Group  
 Patients already on metformin 500mg bd & Glipizide 5mg bd are 
continued with the same for next 3 months. 
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TREATMENT SCHEDULE: 
Control Group A 
  METFORMIN 500mg BD +GLIPIZIDE 5 mg BD + 
BROMOCRIPTINE 1.6 mg OD for a period of 12weeks. 
Study Group B: 
  METFORMIN 500mg BD +GLIPIZIDE 5 mg BD for a period of    
12weeks. 
FOLLOW UP VISITS: 
   After baseline investigations and clinical examination the patients in 
each group. Group A [control group] and group B [study group] were given 
medications for 2 weeks. At the end of every 2 weeks patients were advised to 
return back the empty packs of medicines to assure compliance. After getting 
clinical history and clinical examination patients were given medicines for 
next 2weeks.At the end of each month Fasting Blood sugar and postprandial 
blood sugar were collected for each patient. This was done repeatedly for 3 
months. Adverse effects were noted during every visit and if any serious 
adverse affects patients were asked to report immediately to hospital and 
investigator. 
 At the end of 3rd month FBS, PPBS and Hba1c were done. Also   
baseline blood investigations done at the end of 3 months. After this Patients 
were advised to follow their regular drugs after the study and dosage adjusted 
according to their blood glucose level. Patients were monitored for any 
adverse effects for 2 weeks after withdrawal of Bromocriptine. 
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ASSESMENT OF EFFICACY OF BROMOCRIPTINE: 
1.  Was done by   measuring for each patient in the both study group and 
control group at baseline, 1st month, 2nd month and at 3rd month. 
 2.  Hba1c was done at baseline [at the start of the study] and at the end of 
the study for each patient in both study and control group. By 
comparing the results of each group the efficacy of Bromocriptine in 
decreasing HbA1C was evaluated. 
ASSESESMENT OF SAFETY OF BROMOCRIPTINE: 
1.   Patients were advised to report any adverse effects immediately and at 
each visit to the investigator. 
2.  Blood pressure monitoring, baseline laboratory investigations, 
Hemoglobin, total count, differential count, Erythrocyte Sedimentation 
Rate(ESR) ,LFT, Blood urea, serum creatinine, blood lipid profile, 
urine routine  ,Chest XRAY, ECG were done and recorded for each 
patient at the start of the study and compared to the same tests done at 
the end of the study.so that the cardiac, renal ,pulmonary and hepatic 
adverse effects and effect on lipid profile was evaluated before and 
after the study period. 
3.  The data   from investigations were collected, tabulated and analyzed 
stastically.  
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STUDY FLOW CHART: 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
SCREENED PATIENTS 
N=200 
RECRUITED 
PATIENTS N=140 
RANDOMISATION 
CONTROL GROUP A  
N = 70 
 
STUDY GROUP B 
N = 70 
Metformin 500mg Bd 
+Glipizide 5 Mg Bd + 
Bromocriptine 1.6 mg  OD for 
a period of 12weeks. 
Metformin 500mg Bd 
+Glipizide 5 Mg Bd For A 
period of 12weeks. 
EVALUATION AT BASELINE, 1ST, 
2ND, AND AT 3RD MONTH. 
Stastical Analysis of Results of 118 Patients Who 
Completed the Study [58 Patients In Control 
Group And 60 Patients In Study Group 
12 dropouts in 
control group 
10 dropouts in 
study group 
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RESULTS 
 
 Totally 200 patients with T2DM was screened for this study. Out of 
200, 38 patients had hypertension 12 had Dyslipidemia 10 patients had 
elevated serum creatinine levels. These 60 patients were excluded from the 
study. 140 patients who satisfy the inclusion criteria were recruited for this 
study. 
 Out of 140 patients, only 118 patients completed the study. 14 patients 
were lost to follow up. 8 patients were withdrawn from the study due to side 
effects.  Of the 8 patients,4 developed hypoglycemia frequently (2 in group A , 
2 in group B) and 4 patients had , nausea and vomiting . (1 in group a, 3 in 
group B). Only 118 patients completed the study, results of those 118 patients 
were analyzed stastically. Statistical analysis was done with paired and 
unpaired t test. Age distribution and sex distribution were analyzed using: 
PEARSON CHISQUARE TEST. Stastical package for social sciences -SPSS 
16 was used for stastical analysis of results. 
Table 1a: Number of Patients Completed And Number Of Dropouts 
Groups Total no of patients 
No. of patients 
completed the 
study 
No of dropouts [22] 
Lost Side effects 
Group A [control 
group]. 
70 58 9 3 
Group B study group  70 60 5 5 
Total 140 118 14 8 
 
 Table 1A shows total number of patients who completed the study and 
total number of drop outs from the study in both control group and study 
group. 
56 
 
Table 1b: Age Distribution 
Age in years 
Control Study Pearson Chi 
Square Test N % N % 
30-40 4 6.7O 6 10 
X2 =1.06 
P=0.78 
41-50 14 23.30 15 25  
51-60 34 58.30 30 50  
>61 6 11.70 9 15  
TOTAL 58 100 60 100  
 
    S 0.05 is significant; p0.01 is highly significant; p 0.001 very 
highly significant. 
 Table 2 displays no stastically significant difference both control and 
study groups regarding distribution of age 
Figure 1: Age Distribution of Control And Study Groups 
 
 Figure 1shows age distribution among control and study groups 
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Table 2: Sex Distribution 
Gender 
Control Study Pearson Chi Square Test 
N % N % 
X2= 0.134 
P=0.7 
F 32 55% 31 51.7% 
 
M 26 45% 29 48.3% 
 
Total 58 100% 60 100% 
 
  
   p 0.05 is significant; p0.01 is highly significant; p 0.001 very 
highly significant. 
 Table 2 shows no stastically significant difference both control and 
study groups regarding distribution of gender. 
Figure 2: Sex distribution of control and study groups. 
 
 Figure 2 shows sex distribution among control and study groups.  
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Table 3:  Body Mass Index Distribution 
Body mass Index 
Control Study Students  
independent t test Mean ± SD Mean± SD 
Baseline 26.36 ± 2.389 26.03± 2.02 P=0.42 
After 3months 26.1± 2.456 26.01± 2.045 P=0.825 
Paired T test P=0.06 P=0.19  
 
    S 0.05 is significant; p0.01 is highly significant; p 0.001 very 
highly significant 
Figure 3: Body mass index distribution of control and study groups. 
 
 Figure 3 shows BMI distribution before and after the study. 
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 Table 3 and figure 3 shows BMI Distribution at the start of the study 
and after 3 months.  No statistically significant difference between study & 
control groups in mean BMI before drug administration at the start of the 
study. 
 At the end of the study there is a mild decrease in mean BMI in both 
control and study groups. The decrease in BMI in the study group and control 
group is not stastically significant. 
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EVALUATION OF EFFICACY OF BROMOCRIPTINE IN 
DECREASING BLOOD SUGAR: 
Table 4: Fasting blood sugar of control and study groups. 
 Month 
Fasting 
Blood 
Sugar 
Control Study Student 
Independent 
“t test” Mean ±sd Mean±sd 
0 month Baseline 188.17±47.461 179.8±34.018 P=0.27 
I month Visit 1 179.1±47.322 161.67±43.422 P=0.038* 
II month Visit 2 180.2±52.371 151.558±38.729 P=0.001** 
III month Visit 3 164.6±46.466 131.65±27.042 P=0.0001*** 
 
Table 4a: Fasting Blood Sugar [Before and After Study] 
Fasting Blood Sugar 
Control Study 
Mean ± SD Mean ± SD 
At baseline 188.17±47.461 179.8±34.018 
After 3 months 164.6±46.466 131.65±27.042 
 Paired t test T=6.79, p = 0.0001 T=15.3,p=0.0001 
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant 
 Table 4 shows mean FBS of control and study groups at baseline and at 
every visit. 
 Table 4A displays the comparison of mean FBS before and after 3 
months in both control and study groups. 
61 
 
Figure 4: Fasting Blood Sugar of Control And Study. 
 
  Table 4,4a And Figure 4   demonstrate there is no statistical difference 
between mean FBS at baseline in control and study groups. But there is 
stastically significant difference in mean FBS between   control and study 
groups at subsequent visits. [Students independent t test was used].  
 At the end of the study there is decrease in mean FBS in both study and 
control groups. 
 Controlgroup: Decrease of mean FBS seen from baseline 188.17 to 
164.6[23.57] after 3 months 
 Study Group:  Decrease of mean FBS seen from baseline   179.8 to 
131.65[48.15] after 3 months 
  When paired t test was used to compare mean FBS before and after 
drug administration statistically significant reduction is seen in study group 
(P=0.0001) and also in control group (P=0.0001) at the end of the study. 
179.8
161.67
151.58
131.65
188.17
179.1 180.2
164.6
0
20
40
60
80
100
120
140
160
180
200
baseline visit 1 visit2 visit 3
fa
st
in
g 
bl
oo
d 
su
ga
r
Case
Control
62 
 
Table 5- Postprandial Blood sugar of Control And Study Groups 
Month 
Postprandial 
Blood 
Sugar 
Control Study Student 
Independent 
“t test” Mean ± sd Mean ± sd 
0 month BASELINE 281.55±55.984 297.82±58.447 P=0.122 
I month Visit 1 227.72±60.964 269.4±57.035 P=0.00001*** 
II month Visit 2 223.95±59.741 261.70±64.498 P=0.001** 
III month Visit 3 252.37±63.43 221.38±59.65 P=0.007** 
 
Table 5a- Postprandial Blood sugar [Before And After Study] 
Postprandial blood 
sugar 
Control Study 
Mean ± sd Mean ± sd 
At baseline 281.55±55.984 297.82±58.447 
After 3 months 252.37±63.43 221.33±59.65 
 Paired t test T=6.09,p=0.0001 T=16.63,p=0.0001 
P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant 
 Table 5 shows mean PPBS of control and study groups at baseline and 
at every visit. Table 5A displays the comparison of mean PPBS before and 
after the study in both groups. [Control and study group] 
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figure 5: Postprandial blood sugar of control and study groups. 
 
 Table 5,5a and Figure 5 demonstrate there is no statistical difference 
between mean PPBS at baseline in control and study groups. But there is 
stastically significant difference in   mean PPBS between   control and study 
groups at subsequent visits.  
 At the end of the study there is decrease in mean PPBS in both study 
and control groups. 
 Controlgroup: Decrease of mean PPBS seen from baseline 281.55 to 
252.37[29.18] after 3 months. 
 Study Group:  Decrease of mean PPBS seen from baseline   297.82 to 
221.33[76.49] after 3 months.  
  When paired t test was used to compare mean PPBS before and after 
drug administration statistically significant reduction is seen in study group at 
the end of the study [  P = 0.0001]and also in the control group.[p=0.0001]. 
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Table 6   : HbA1c [Before and After Study] 
HbA1c 
Control Study Student 
independent t test Mean ± SD Mean ± SD 
Baseline 7.632±0.688 7.54±0.618 P=0.445 
After 3 months 7.325±0.667 7.015±0.542 P=0.006 
 Paired t test P=0.001 P=0.0001  
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
Figure 6: HbA1c Before And After Study in Both Groups 
 
 Table 6 and Figure 6 displays the comparison of mean HbA1C before 
and after the study in both groups. . [Control and study group]. 
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  Table 6 & Figure 6   demonstrate   that there is no statistical difference 
between mean HbA1C at baseline in control and study groups. But there is 
stastically significant difference in mean HbA1C   between   control and study 
groups at the end of 3 months. [P=0.006][Student independent t test is used] 
 At the end of the study there is a decrease in mean HbA1C in both 
study and control groups. 
 Control group: Decrease of mean HbA1C seen from baseline- 7.63 to 
7.32 [0.3] after 3 months. 
 Study Group:  Decrease of mean HbA1C seen from baseline -   7.54 to 
7.01 [0.5] after 3 months. 
 When paired t test was used to compare mean HbA1C before and after 
drug administration statistically significant reduction is seen in the study group   
and in the control group at the end of the study. The reduction in the study 
group is higher [p=0.0001] than the control group [p=0.001] at the end of the 
study. 
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Table 7: total cholesterol before and after the study. 
Total Cholesterol 
Control Study Student 
Independent 
“t  test” Mean ± SD Mean ± SD 
Baseline 243.22±44.394 254.85± 27.296 P=0.085 
After3 months 241.72±43.985 247.22.± 25.634 P=0.402 
 Paired t test P=0.003 P=0.0001  
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
Figure 7: Total cholesterol before and after the study in  both groups 
 
 
 Table 7 and Figure 7 displays the comparison of mean Total cholesterol 
before and after   3months between control and study group. 
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 Table 7 and Figure 7 demonstrates there is no statistical difference 
between mean Total cholesterol at baseline in control and study groups. 
 At the end of the study there is decrease in means total cholesterol in 
both study and control groups. 
 Control group: Decrease of mean total cholesterol   seen from baseline 
243.22 to 241.72 [1.5] after 3 months. 
 Study Group:  Decrease seen of mean total cholesterol   from baseline    
254.85 to 247.22[7.6] after 3 months. 
 When paired t test was used to compare mean total cholesterol   before 
and after drug administration statistically significant reduction is seen in study 
group [p=0.0001] and the control group [p=0.003] at the end of the study. But 
the reduction is more in the study group   than the control group. 
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Table 8- LDL before and after the study 
LDL 
Control Study Student 
Independent 
“t test” Mean  ± SD Mean ± SD 
Baseline 160.1±35.384 173.67±26.648 P=0.019 
After 3 months 160.03±34.329 166.3±26.626 P=0.266 
 Paired t test P=0.7 P=0.001  
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
Figure 8: LDL before and after the study in both groups 
 
 
  Table 8 and Figure 8 displays the comparison of mean LDL   between 
the Control and study groups before and after the study. 
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 Table   8 and Figure 8   demonstrates there is no statistical difference in 
mean LDL at baseline between control and study groups... 
 At the end of the study there is decrease in mean LDL in both study and 
control groups. 
 Control group: Decrease   of mean LDL from baseline- 160.1 to 160.3 
[0.2]   after 3 months. 
 Study Group:  Decrease of mean LDL from baseline -173.6 to 166.3 
[7.37]   after 3 months. 
  When paired t test was used to compare mean LDL before and after 
drug administration, statistically significant reduction is seen in study group at 
the end of the study [P = 0.001]. The reduction in control group is not 
statistically significant [P=0.7]. 
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Table 9:  VLDL before and after the study 
VLDL 
Control Study Student 
Independent 
“t test” Mean ± SD Mean ± SD 
Baseline 44.68±23.898 35.2±9.892 P=0.006 
After3 months 43.8±21.812 34.73±8.986 P=0.004 
 Paired t test P=0.3 P=0.2  
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
Figure 9: VLDL before and after the study in   both groups. 
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 Table 9 and Figure 9displays the comparison of mean VLDL before 
and after he study in both groups. [Control and study group] 
 Table 9 And Figure 9 demonstrates there is no statistical difference 
between   Mean VLDL at baseline   in control and study groups. But there is 
stastically significant difference in mean VLDL score   between   control and 
study groups [P=0.004] at the end of 3 months. [STUDENTINDEPENDENT 
“t test”]. 
 Control group: Decrease seen from baseline 44.68-43.8 [0.88] after 3 
months. 
 Study Group:  Decrease seen from baseline   35.2-34.73[0.47] after 3 
months. 
 At the end of the study there is the mild decrease in mean VLDL in 
both study and control groups. When paired t test was used to compare mean 
VLDL before and after drug administration the decrease in mean VLDL is not 
stastically significant   in both groups. 
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Table 10 - TGL Before and After ahe Study 
TGL 
Control Study Student 
Independent 
“t test” Mean ± SD Mean ± SD 
Baseline 178.9±26.476 176.15±34.584 P=0.674 
After3 months 177.44±27.023 166.2±35.773 P=0.064 
 Paired t test P=0.06 P=0.001  
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
Figure 10: TGL before and after the study in both groups. 
 
 
 Table 10 and Figure 10 displays the comparison of mean TGL before 
and after 3 months between Control and study group. 
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 Table 10 and Figure 10 demonstrates there is no statistical difference 
between mean TGL at baseline in control and study groups.  Also there is no 
stastically significant difference in mean TGL scores between   control and 
study groups. [Student Independent “t test”] at the end of the study. 
 At the end of the study there is the decrease in   mean TGL in both 
study and control groups. 
 Control group: Decrease seen from baseline 178.9-177.44 [1.46] after 3 
months. 
 Study Group:  Decrease seen from baseline   176.15 to 166.2 [9.95] 
after 3 months. 
 When paired t test was used to compare mean TGL before and after 
drug administration. In the study group the decrease in   mean TGL is higher 
and statistically significant [P = 0.001].The decrease in mean TGL is not 
stastically significant   in the control group. [P=0.06] 
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Table 11 -HDL before and after the study. 
HDL 
Control Study Student 
Independent 
“t test” Mean ± SD Mean ± SD 
Baseline 39.85±9.426 38.65±8.81 P=0.502 
After3 months 39.63±9.579 38.6±8.681 P=0.576 
 Paired t test P=0.6  P=0.8   
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
figure 11: HDL before and after the study in both groups. 
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 Table 11 and Figure 11 displays the comparison of mean   HDL before 
and after the study in both groups 
 Table 11 and Figure 11 demonstrates there is no statistical difference 
between mean HDL at baseline in control and study groups. Also there is no 
stastically significant difference in mean HDL between   control and study 
groups at end of 3 months.  
 When paired t test was used to compare mean HDL before and after 
drug administration   NO statistically significant change is seen in study group 
as well as the control group. 
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Table 12- Systolic BP before and after the study. 
Mean SBP 
Control Study Student 
Independent 
“t test” Mean ± SD Mean ± SD 
Baseline 128.68±12.598 124.37±10.83 P=0.065 
After3 
months 124.98±9.887 122.5±9.13 P=0.201 
 paired t test P=0.001  P=0.001   
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
Figure 12: Systolic BP Before and After the Study in Both Groups 
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 Table 12 and Figure 12 displays the comparison of mean   SBP before 
and after 3 MONTHS between study and control groups. 
 Table 12 and figure   12 demonstrates there is no statistical difference 
between mean SBP at baseline   in control and study groups.  Also there is no 
stastically significant difference in mean SBP   between   control and study 
groups at the end of 3 months. [Student Independent “T Test”]. 
 At the end of the study there is the decrease in mean SBP in both study 
and control groups. 
 Control group:  Decrease seen from baseline 128.68-124.98[3.64] after 
3 months. 
 Study Group:  Decrease seen from baseline   124.37-122.5[1.87] after 3 
months. 
 When paired t test was used to compare mean SBP before and after 
drug administration the decrease in mean SBP is [P =0.001] stastically 
significant in control group as well as study group. [P =0.001] 
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Table: 13 Diastolic BP before and after the study. 
DBP Control Study Student 
Independent 
“t test” Mean ± SD Mean ± SD 
Baseline 83.05±8.59 79.97±7.987 P=0.062 
After3 months 80.44±6.369 78.83±7.386 P=0.214 
 Paired t test P=0.002  P=0.0001   
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
Figure 13: Diastolic BP Before and After the Study in Both Groups 
 
 Table 13 and Figure 13 displays the comparison of mean   DBP before 
and after the study in both groups. 
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 Table 13 and Figure 13 demonstrates there is no statistical difference 
between mean SBP at baseline   in control and study groups.  Also there is no 
stastically significant difference in mean DBP between control and study 
groups at the end of 3 months. [Student Independent “T Test”]. 
 At the end of the study there is decrease in mean DBP in both study and 
control groups 
 Control group:  Decrease seen from baseline 82.83 to 80.4[2.43] after 3 
months. 
 Study Group:  Decrease seen from baseline 79.9 to 78.83 [1.14] after 3 
months. 
  When paired t test was used to compare mean DBP before and after 
drug administration the decrease in mean DBP is [P = 0.0001] stastically 
significant   in study group and also stastically significant in control group.  
[p=0.002].But the decrease in mean DBP is higher in study group than control 
group. 
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Table 14: Comparison of Reduction   Between Control and Study Groups 
Parameters 
Reduction from baseline 
student 
independ
ent t’ test 
Control Study 
Mean score at 
baseline minus mean 
score at the end 
Mean score at 
baseline minus mean 
score at the end 
BMI 0.258 0.02 P=0.07 
FBS 23.56 48.16 P=0.0001 
PPBS 29.18 76.4 P=0.0001 
HbA1C 0.30 0.52 P=0.001 
Total 
Cholesterol 1.5 7.63 P=0.0001 
TGL 1.5 9.95 P=0.0001 
LDL 0.06 7.36 P=0.0001 
VLDL 0.88 0.46 P=0.647 
HDL 0.25 0.05 P=0.712 
SBP 3.63 1.86 P=0.143 
DBP 2.43 1.13 P=0.289 
*P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
 Table 14 Shows comparisons of reduction [from baseline to end of the 
3 month] of parameters of control group   with the reduction [from baseline to 
end of the 3 month] of parameters of study group.  
 The reduction of FBS, PPBS, HbA1C, total cholesterol, TGL and LDL 
in the study group is more than the reduction seen in the control group and it is 
statistically significant. 
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Table: 15 Comparisons  of adverse events 
Group 
Adverse events 
Total 
Chi-square 
test Present Absent 
Control 3 55 58 X2=0.42 
P =3.87 Study 5 55 60 
 *P d 0.05 Significant; ** Pd0.01 highly significant ***Pd0.001 very highly 
significant. 
 Table 15: shows the comparison   of adverse events among groups and 
their stastical significance. 8 patients withdrawn from the study due to adverse 
effects. [3 in control group, 5 in study group].  Of the 8 patients,4 developed 
hypoglycemia frequently (2 in group A , 2 in group B) and 4 patients had , 
nausea and vomiting . (1 in group   a, 3 in group B. 
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Table 16: Side effects observed 
S .No Side effects 
Control group Study group 
N % N % 
1 Nausea, vomiting 1 1.7% 3 5% 
2 Diarrhea - - - - 
3 Giddiness - - - - 
4 Headache - - - - 
5 Hypoglycemia 2 3.4% 2 3.3% 
6 Psychosis - - - - 
7 Erythromelalgia - - - - 
8 Orthostatic hypotension - - - - 
 
 Table 16 shows analysis of various adverse effects in control and study 
groups. 
 No stastically significant difference seen   between the adverse effects 
of study and control groups. 
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BIOCHEMICAL EVALUATION OF SAFETY OF BROMOCRIPTINE. 
Table 17: Shows the hematological and biochemical parameters of the 
control group and the study groups at the start and end of the study. 
Parameter Group 
At the start At the end Student 
paired t- test Mean  ± SD Mean  ± SD 
 Hemoglobin 
Control 10.94±0.96 11.13±1.05 P=0.45 
Study 10.92±0.95 1.28±1.01 P=0.15 
Total 
Leucocyte 
Count 
Control 9788±1630. 9586.84±1514.50 P=0.66 
Study 9720±1618.37 9634.23±1583.23 P=0.56 
ESR 
Control 11.68±1.38 11.54±1.60 P=0.69 
Study 11.36±1.21 11.66±1.47 P=0.35 
Blood Urea 
Control 20.70±2.40 20.84±2.54 P=0.83 
Study 20.56±2.33 20.88±2.82 P=0.63 
Serum 
Creatinine 
Control 0.77±0.13 0.77±0.12 P=0.86 
Study 0.76±0.13 0.78±0.13 P=0.30 
SGOT 
Control 17.64±4.52 17.51±4.04 P=0.90 
Study 17.88±4.36 17.43±4.38 P=0.72 
SGPT Control 12.02±4.03 18.04±4.58 P=0.36 
Study 16.72±4.14 17.78±5.17 P=0.30 
Pd0.05 Significant; pd0.01 highly significant; P=d0.001 very highly 
significant. 
 Statistical analysis shows no significant difference in Hb, Total count, 
ESR, B Urea, S-creatinine, SGOT, and SGPT levels   between study & control 
groups. 
 Therefore no significant change seen in both study and control groups 
regarding hematological and biochemical parameters during the study. 
 ECG & CXR and urine routine were also within normal study both at 
the start of the study and at the end of the study in both groups. 
84 
 
DISCUSSION 
 
 Diabetes Mellitus is becoming more common in both urban and rural 
population. Medical expenditures are high for treating diabetes mellitus and its 
complications76 
 [In spite of regular treatment, hyperglycemia goes unchecked in many 
patients.77 Many drugs like sulphonylureas and thiazolidinedione’s are not 
used optimally because side effects limit  their use. Inventions of new drugs 
are increasingly needed   in the treatment of diabetes mellitus. 
 Bromocriptine which is used in other conditions is found to be useful in 
diabetes mellitus. More studies are needed to evaluate the efficacy and safety 
of Bromocriptine   in diabetic population of Tamilnadu. Hence this study was 
done to evaluate the efficacy and safety of Bromocriptine in patients with 
Diabetes mellitus coming to Diabetic outpatient department of Chengalpattu 
medical college and hospital, Tamilnadu. 
 In this study, diabetic patients were divided in to two groups. Patients 
received Bromocriptine of 1.6mg in addition to metformin and glipizide in the 
study group and the results were compared   to that of control group   who 
received only metformin and glipizide. The results of the study is discussed 
below:  
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DEMOGRAPHIC CHARECTERISTICS 
Age   distribution   
 When analyzed statistically and it is found   there was no stastically 
significant difference between mean age of   control and study group at 
baseline. 
Sex  Distribution  
 In the control group, total number of Males were 26, and total number 
of females were 32. In the study group, total number of Males   were 29,  and 
total number of females were 31.Sex distribution was stastically 
analysed.There was no stastically significant difference between of study and 
control group regarding sex distribution at the start of the study. 
Body Mass Index [BMI]: 
  Mean BMI of control group was 26.36, mean BMI of study group was 
26.03 at baseline and there was no stastically significant difference between 
mean BMI of study and control group at the baseline. [P=0.42]. 
 In the control group the end of 3 months,BMI decreased from (26.36 to 
26.1 ) about 0.26[p=0.06].In the study group at the end of 3 months BMI 
decreased from(26.03 to 26.01)  0.02.[p=0.19].Therefore, both the study and 
control group show decrease in the BMI after 3 months. The reduction is not 
statistically significant in both the groups. 
           Many studies  by Meier et al, Cincotta et al shows weight loss caused 
by Bromocriptine78,79 
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 Some studies show inconsistent results, such as studies by Pijl et al, 
Aminorroaya et al, Masada et al80, 81, 82...but weight gain is not caused by 
Bromocriptine in any of the previous studies. 
           In our study, result shows that there is only mild decrease in mean BMI 
which is not significant. 
Effect on FBS 
 AT Baseline, the FBS of control group and study group did not display 
any statistically significant difference.  
 But, at the end of 3 months FBS shows DECREASE in FBS in both 
control [23mg/dl] and study [48mg/dl] groups. The decrease in FBS is 
stastically significant in both study [P=0.0001] and control groups. 
[P=0.0001]. The decrease in FBS is higher in the study group than the control 
group. 
 Thus In this present study combination of Bromocriptine along with 
metformin and glipizide caused more reduction in FBS than combination of 
metformin and glipizide alone. 
   Previous Studies by Pijl et al80, Shows there was a decrease in FBS to 
about 18mg/dl   in Bromocriptine group patients. Previous studies by Ramatke 
at al83shows reduction in mean FBS  in bromocriptine+Metformin group about 
44.31mg/dl  at 12 Weeks which  was stastically significant.[p<0.05] .  
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EFFECT ON PPBS  
 AT Baseline, the PPBS of control group and study group did not 
display any statistically significant difference.  
 But, at the end of 3 months   DECREASE in PPBS in both control 
[29mg/dl] and study [76mg/dl] groups was seen. The decrease in PPBS is 
stastically significant in both study [P=0.0001] and control groups. 
[P=0.0001]. The decrease in PPBS is higher in the study group than the 
control group. 
 Thus In this present study combination of Bromocriptine along with 
metformin and glipizide caused more reduction in PPBS than combination of 
metformin and glipizide alone. 
      Similar studies done by Ramteke at al 83showed statistically significant 
reduction of PPBS About 43.71mg/dl at 12 weeks. [P<0.05] compared to 
baseline.  Another study done by Kamath et al84, shows the reduction in 
postprandial sugar was 16 mg/dl in the Bromocriptine group. 
 HbA1C   
 AT Baseline, mean HbA1C of control group and study group did not 
show any statistically significant difference.  
 But, at the end of 3 months this study shows DECREASE in 
meanHbA1C in both control [0.3%] and study [0.5%] groups. The decrease in 
mean HbA1C is stastically significant in both study [P=0.001] and control 
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groups. [P=0.0001]. The decrease in mean   HbA1C is higher in the study 
group than the control group. 
 Thus In this present study combination of Bromocriptine along with 
metformin and glipizide caused more reduction in HbA1C than combination 
of metformin and glipizide alone. 
 Similar studies done by Ramatke at al83, showed reduction in mean 
HbA1C to about 0.74% in the group treated with Bromocriptine compared to 
the other groups. [P< 0.05]. Also   studies by Pijl et al80 found patients on 
Bromocriptine group found a stastically significant reduction about 0.6% of 
HbA1c Compared to other groups.  
            Clinical conditions like   obesity, insulin resistance, hypertension, and 
CKD reveal   high NE plasma levels, sympathetic over activity, and 
hyperprolactinemia which in turn was due to reduced dopaminergic tone. 
Dopamine agonists such as Bromocriptine improve these clinical  
conditions85, 86, 87, 88.   
EFFECT ON LIPID PROFILE 
 In our study, fasting lipid profile [LDL, VLDL, HDL, TGL, TOTAL 
CHOLESTEROL] was done at the start and end of the study in both study and 
control groups. 
 The results show that there is stastically significant reduction in Total 
cholesterol in the study group [p=0.0001] and also in the control group. 
[p=0.003]. But the reduction was   higher in the study group.  
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 There is stastically significant reduction in LDL in the study group 
[p=0.001]  but in the control group [p=0.7] no stastically significant reduction 
was   seen at the end of the study. 
 There is stastically significant reduction in TGL in the study group 
[p=0.001] but in the control group [P=0.06] no stastically significant reduction 
was   seen at the end of the study. 
 There was no stastically significant reduction in VLDL in the study 
group as well as in the control group seen at the end of the study. Also there is 
no significant increase in the HDL level in both control and study group when 
compared to baseline.  
 However there is no adverse effect of causing increase in blood lipid 
levels in study group and also in control group. Several anti-diabetic drugs 
such as rosiglitazone caused adverse effect on lipid profile. In our study, no 
adverse effect on serum lipid was found to be caused by Bromocriptine. 
  Similar studies were done to evaluate the effect of Bromocriptine on 
lipid profile. 
  Some studies showed a stastically significant results depicting decrease 
in fasting and post-prandial triglycerides by 72 and 63 mg/dl (P < 0.005) and 
fasting and post-prandial free fatty acids by 150 and 165 qr/l (P < 0.05), 
compared to placebo.89 
 Some other studies showed insignificant results when the effect of 
Bromocriptine on lipid profile is compared to placebo group90. 
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  Other hematological and biochemical parameters done at baseline and 
at the of 3 months show no abnormal effect on it caused by bromocriptine 
administration. 
 Monitoring for adverse events also showed no major life threatening 
adverse effects. Mild adverse effects like nausea, vomiting and hypoglycemia 
occurred during the study period. .There was no stastically significant 
difference between the adverse effects in the study and control groups. 
 So Bromocriptine quick release is a safe drug that can be used in   type 
2 Diabetesmellitus. It is available in India as tablet Bromocriptine Mesylate 
I.P equivalent to Bromocriptine 0.8 mg. 
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SUMMARY 
 
 The results of   this    randomized open labeled clinical trial throw light 
on the effect of Bromocriptine in diabetes mellitus 
 The results show in Type 2 Diabetes Mellitus, add on therapy of 
BROMOCRIPTINE QR to metformin and glipizide  in the study group, when 
compared to the control group of patients receiving metformin and glipizide 
alone 
 Have caused 
a) significant reduction in the Fasting blood sugar, Postprandial blood 
sugar,HbA1C 
b)  Significant reduction in Total cholesterol, TGL and LDL. 
c) Significant reduction in systolic and diastolic BP. 
 There are no serious adverse effects observed in Type 2 Diabetes 
Mellitus patients taking Bromocriptine QR 1.6 mg OD. 
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CONCLUSION 
 
The conclusion of this study is as follows 
 Bromocriptine is   effective in reducing   fasting blood glucose, 
postprandial blood glucose and HbA1c. 
 Bromocriptine also has favorable effect on BMI and lipid profile and 
blood pressure. 
 Bromocriptine in doses used 1.6mg/day is found to be safe.  No major 
adverse effects were seen during the use of Bromocriptine. 
  Bromocriptine has advantages of not causing weight gain, and 
dyslipidemia and hypoglycemia. 
 Further large scale studies are necessary to highlight the effect of 
Bromocriptine on lipid profile and hypertension. 
  In Modern India, more drugs acting through multiple mechanism of 
action are necessary   to challenge DM in the future. 
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INFORMATION TO PARTICIPANTS 
 
Principal Investigator: -   Dr.M.Nithyapriya D.Diab., 
MD Pharmacology Postgraduate 
Chengalpattu medical College 
Chengalpattu. 
 
Nameoftheparticipant: -
_______________________________________________________ 
Title  : EFFICACY AND SAFETY OF BROMOCRIPTINE QR AS AN 
ADD ON  THERAPHY WITH METFORMIN AND GLIPIZIDE IN 
TYPE 2 DIABETES  MELLITUS PATIENTS an OPEN LABEL 
RANDOMIZED CONTROLLED STUDY 
This study is conducted in our institution, Chengalpattu medical College, 
Chengalpattu. 
You are invited to take part in this study. The information in this document is 
meant to help you to decide whether or not to take part. Please feel free to able 
if you have any queries or concerns. 
You are being asked to participate in this study conducted in the department of 
general medicine and department of pharmacology, Chengalpattu Medical 
College. 
Purpose of research: 
To do a study of efficacy and safety of Bromocriptine QR as an add on 
therapy to diabetic treatment metformin, glipizide in Type 2 Diabetic mellitus 
patients. 
The study is conducted with permission from the Institutional ethical 
committee. 
Study design  : Randomized control study. 
 
 
 
 Study Procedure 
 
The study involves laboratory investigations including blood glucose 
estimation and regular clinical assessment of patient’s recessing the new drug 
Bromocriptine QR for a period of 3 months. 
Bromocriptine QR 1.6 mg tablets will be given to take once daily in the 
morning. 
Periodic assessment of blood glucose levels will be done at the start of 
therapy and regular monthly intervals and at the end of the study (3 months. 
You will be asked to review at regular intervals. At each visit the doctor will 
examine you. 
In addition, if you notice any physical or mental change, you must 
contact the persons listed at the end of the document. 
 You may have to come to hospital for examination and investigations 
apart from your scheduled visits if required.  
You must not participate if you are pregnant, breast feeding a child or 
suffering from any serious medical illness like coronary artery disease, kidney 
or liver disease, cancer or any surgical illness. 
Benefits of the study : 
 The results of the research may provide benefits to the society in term 
of thereauptic advancements in diabetic patients and benefits future of diabetic 
patient’s. It helps to reduce the burden of diabetes in our society. 
 
 
 
 
 
jfty; gbtk; 
Kjd;ik Ma;thsh;  : kUj;Jth;. k. epj;agphpah> 
     nrq;fy;gl;L kUj;Jtf; fy;Y}hp 
 
gq;F ngWgthpd; ngah; :-
………………………………………………………………… 
jiyg;G :  rh;f;fiu Nehahspfspd; ,uj;j rh;f;fiu msit 
Fiwf;Fk;    GNuhNkhfphpg;bd; vd;w kUe;jpd; 
jd;ikiaAk;> mjd;       ek;gfj;jd;ikiaAk; 
mwptJ Fwpj;J elj;jg;gLk; Ma;T. 
 ,e;j Ma;T nrq;fy;gl;L muR kUj;;Jtkidapd; ePhpopT Neha; 
rpfpr;if gphptpy;> elj;jg;gLfpwJ. ,e;j Ma;T kUj;Jth; k. epj;agphpah 
mth;fshy; mDgtk; tha;e;j kUj;Jth;fspd; cjtpNahL 
elj;jg;gLfpwJ. 
Ma;tpd; Nehf;fk;   
 nghJthf rh;f;fiu Nehahspfs; vLj;Jf;nfhs;Sk; kUe;jhdJ> 
gf;ftpisTfis cz;lhf;Ftjhf cs;sJ. ,jidf; fUj;jpy; 
nfhz;Lk;> rhp nra;Ak; Kaw;rpahfTk; ,e;j GNuhNkhfphpg;bd; vd;w 
kUe;ij gad;gLj;jp> rh;f;fiu Nehia Fzg;gLj;Jtjpy;> Mgj;jhd 
gf;ftpisTfs; ,y;yhky; rh;f;fiuia Fiwf;f ,e;j Ma;T 
elj;jg;gLfpwJ. 
Ma;Tf;fhd nray; Kiwfs;  
 rh;f;fiu NehahspfSf;F> rh;f;fiu Neha;f;fhd kUe;JfSld;> 
GNuhNkhfphpg;bd; vd;w kUe;J toq;fg;gLk;. 
 GNuhNkhfphpg;bd; vd;w kUe;jpid 1.6 kpy;ypfpuhk; vd;;w mstpy;> 
jpdKk; xUKiw fhiyapy; cl;nfhs;s Ntz;Lk;. 
 ,e;j kUe;jpid cl;nfhs;Sk; rh;f;fiu NehahspfSf;F> ,uz;L 
thuj;jpw;F xUKiw rh;f;fiu msit ghpNrhjpg;gjw;fhf> ,uj;j 
ghpNrhjid Nkw;nfhs;sg;gLk;. 
 mJkl;Lky;yhky;> nkhj;j cly; ghpNrhjidAk; elj;jg;gLk;.  
EiuaPuy;> fy;yPuy;> rpWePufk; Mfpatw;wpd; nray;ghl;bid mwptjw;fhd 
rpwg;G ,uj;jg;ghpNrhjidAk; nra;ag;gLk;. Ma;T elj;jg;gLk; fhyk; 3 
khjq;fs;.  
 
 
 xt;nthU tUifapYk; rh;f;fiu Nehahspfs;> kUj;Jtuhy; 
rpwg;ghf ftdpf;fg;gLthh;fs;. 
 GNuhNkhfphpg;bd; kUe;jpid cl;nfhs;Sk;  rh;f;fiu 
NehahspfSf;Fk; kUe;jpid vLj;Jf; nfhs;shj rh;f;fiu 
NehahspfSf;Fk; ,ilNaahd rh;f;fiu mstpd; fl;Lg;ghL 
tpj;jpahrj;ij mwpa ,e;j Ma;T cjTk;. ,e;j Ma;tpy; 
gq;nfLj;Jf;nfhs;sTk;> gad;gLj;jpf; nfhs;sTk; rh;f;fiu Nehahspfs; 
Nfl;Lf;nfhs;sg;gLfpwhh;fs;. 
 ,e;j Ma;tpy; Ra tpUg;gj;Jld; gq;Nfw;f Kd;te;jhy; kl;LNk 
fye;Jf;nfhs;s KbAk;. Ma;tpy; gq;nfLj;Jf;nfhs;Sk; rh;f;fiu 
Nehahspfspd; nrhe;j tpguq;fs; vJTk; ntspaplg;gl khl;lhJ. 
 NehahspfSf;F Vw;gLk; ve;jtpjkhd njhe;jpuTfisAk; 
kUj;Jthplk; njhptpf;fyhk;. mjw;fhd rpfpr;ir clNd toq;fg;gLk;. 
 fh;g;gpzp ngz;fs;> jha;g;ghy; Gfl;Lk; ngz;fs; ,e;j Ma;tpy; 
fye;Jf;nfhs;sf; $lhJ. 
 ,Uja Neha;> rpWePuf Neha;> fy;yPuy; Neha; Mfpatw;why; 
ghjpf;fg;gl;lth;fSk;> rkPgj;jpy; mWit rpfpr;ir nra;Jf; 
nfhz;lth;fSk; ,e;j Ma;tpy; gq;Nfw;f $lhJ. ,e;j Ma;tpd; 
KbTfs; midj;Jk;> gq;Fnfhz;l rh;f;fiu Nehahspfs; midtUf;Fk; 
njhptpf;fg;gLk;. 
 ,e;j Ma;tpid elj;Jtjw;F kUj;Jtkidapd; Kiwahd 
mDkjp ngwg;gl;Ls;sJ. 
,e;j Ma;tpd; gad;fs;: 
 rh;f;fiu Nehahspfspd; vjph;fhy tho;f;if Kiwapy; ey;y 
Kd;Ndw;wk; Vw;glTk;> ,e;Nehahy; rKjhaj;jpYk;> FLk;gj;jpYk; Vw;gLk; 
ghjpg;gpid Fiwf;fTk; ,e;j Ma;T cjTk;. 
 ,e;jpahtpy; rh;f;fiu Nehahspfspd; vz;zpf;if mjpfkhfpf; 
nfhz;Nl tUfpwJ. ,jid fl;Lg;gLj;j gy;NtW Gjpa kUe;Jfis 
gad;gLj;JtJ mtrpakhfpwJ. ,e;j Ma;T mjw;F toptFf;Fk;. 
 
Ma;;thshpd; ifnahg;gk;    gq;FngWk; Nehahspapd; ifnahg;gk; 
ehs; : 
,lk; : 
 
 
INFORMED CONSENT FORM 
 
(This is only a guideline –Relevant changes to be made as per the study 
requirements) 
Title of the study :  EFFICACY AND SAFETY OF 
BROMOCRIPTINE QR AS AN ADD ON 
THERAPHY WITH METFORMIN AND 
GLIPIZIDE IN TYPE 2 DIABETES 
MELLITUS PATIENTS; AN OPEN LABEL 
RANDOMIZED CONTROLLED STUDY 
Name of the participant : 
______________________________________________ 
Name of the Investigator : Dr.M.Nithyapriya 
Name of the Institution : Chengalpattu Medical College Hospital 
Documentation of the informed consent. 
I _________________________________have read the information in this 
form (or it has been read to me).I was free to ask any questions and they have 
been answered. I am over 18 years of age and, exercising my free power of 
choice, hereby give my consent to be included as a participant in ‘efficacy and 
safety of Bromocriptine QR as an add on therapy with Metformin and 
Glipizide in type 2 diabetes mellitus patients; an open label randomized 
controlled study’ 
1. I have read and understand this consent form and the information 
provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the 
investigator. 
5. I have been informed the investigator of all the treatments I am taking 
or have taken in the past______________________including any 
native (alternative) treatment. 
 
 
6. I have been advised about the risks associated with my participation in 
this study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms. 
8. I have not participated in any research study within the 
past____________________. 
9. I have not donated blood within the past_________________- Add if 
the study involves extensive blood sampling. 
10. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in 
this hospital. 
11. I am also aware that the investigator may treatment my participated in 
the study at any time for any reason, without my consent. 
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt.Agencies, and IEC. I understand that they 
are publicly presented. 
13. I have understood that my identity will be kept confidential if my data 
are publicly presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
 
 I am aware that if I have any question during this study, I should 
contact the Investigator. By signing this consent form I attest that the 
information given in this document has been clearly explained to me and 
understood by me, I will be given a copy of this consent document. 
For adult participants: 
 Name and signature/thumb impression of the participant (or legal 
representative if participant incompetent) 
Name____________________________________signature_______________
______Date_______________ 
Name and signature of impartial witness (require for illiterate patients) 
 
 
Name____________________________________signature_______________
______Date_______________ 
Address and contact number of the impartial witness: 
_______________________________________________________________
_________________________ 
Name and signature of the investigator or his representative obtaining consent: 
Name____________________________________signature_______________
______Date_______________ 
For children being enrolled in research: 
Whether child’s assent was asked: Yes/No 
(If the answer to be above question is yes, write the following phrase: 
You agree with the manner in which assent was asked for from your child and 
given by your child. You agree to have your child take part in this study. 
(If answer to be above question No, give reason: ______________________ 
Although your child did not or could not give his or her assent, you agree to 
your child’s participation in this study. 
Name and signature of/thump impression of the participant’s parent(s) (or 
legal representatives) 
Name____________________________________signature_______________
______Date_______________ 
Name____________________________________signature_______________
______Date_______________ 
Name and signature of impartial witness (require for parents of participant 
child illiterate): 
Address and contact number of the impartial witness: __________________ 
_______________________________________________________________ 
Name and signature of the investigator or his representative obtaining consent: 
 
 
Name____________________________________signature_______________
______________________Date_______________ 
NOTE:- 
 For observational studies in nature or those in which only patient’s 
tissue, body fluids are collected for any kind of analysis the following 
elements in the patient information leaflet will need be included – background 
of the study the purpose for which the sample will be used: confidentially of 
data are right to refuse to give specimens should be included. Points 6, 
7,8,9,10,11 of consent document may be excluded in such cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xg;Gjy; gbtk; 
jpU/jpUkjp……………………………………………………………
…………...……………………………………………………………………
………………………………………..…………………………………………
…………………………………….. 
 tpyhrj;jpy; trpf;Fk; ehd;> vdf;F mspf;fg;gl;l jfty; gbtj;jpy; 
cs;s tpraq;fis gbj;Jk;> Nfl;Lk; Ghpe;Jf; nfhz;Nld;. 
,e;j Ma;T kUj;Jth;. k. epj;agphpah mth;fshy;> mDgtk; 
tha;e;j kUj;Jth;fspd; cjtpNahL nrq;fy;gl;L muR kUj;Jtkid> 
ePhpopT Neha; rpfpr;ir gphptpy; elj;jg;gLfpwJ vd;gij mwpNtd;. 
‘GNuhNkhfphpg;bd;’ kUe;Jld;> ePhpopT Neha;f;fhd kUe;Jk; cld; 
toq;fg;gLk; vd;gij njhpe;Jf; nfhz;Nld;. 
,e;j Ma;tpw;F Njitahd ,uj;jg; ghpNrhjidfSf;F> cl;gl 
rk;kjpf;fpNwd;. 
Ma;tpy; njhlh;e;J gq;Fngw tpUg;gk; ,y;iy vd;why; 
tpyfpf;nfhs;syhk; vd;Wk; mwpe;Jf;nfhz;Nld;. 
Ma;tpd; Kbtpid nrhe;j milahsq;fis ntspaplhky; 
kUj;Jt Muha;r;rpf;fhf gad;gLj;jpf; nfhs;s rk;kjpf;fpNwd;. 
 
ehs;  :         ifnahg;gk; : 
,lk; :    ngah; : 
 
 
 
 
 
PROFORMA 
 
Name:                                          Age:          Sex:             Hospital No:                     
Weight   : 
Present History  : 
Past History   : 
Treatment History  : 
General examination : 
Temperature                        :  
Anemia    :  
Lymphadenopathy  : 
Pedal edema   : 
Jaundice    : 
Pulse Rate   : 
Blood Pressure                    :         
Lab investigations  : 
 
Investigation At the start of 
therapy 
At the end of  8 
weeks 
 Hb% 
Total count  
Differential count 
ESR 
Blood sugar 
Blood urea 
Serum creatinine 
Lipid profile: 
  
Systemic examination: 
x CVS 
x RS 
x Abdomen 
x CNS   
 
 
Total cholesterol 
LDL 
HDL 
TG 
VLDL 
Urine routine 
Urine ketone 
Chest xray 
ECG 
 
Blood glucose estimation: 
 
Blood glucose 
 
Week 
Basal 2nd 4th 6th 8th 
Fasting       
Post prandial      
 
 
 
  
  
 
 
 
patient numberage genderBMI beforehba1c fbs0 ppbs0 fbs1 ppbs1 fbs2 ppbs2 fbs3 ppbs3 BMI ENDhba1c endTOTAL CH BEFORETOTAL CH  AFTGL BEFORETGL AFTERLDL BEFORE2LDL AHDL BEFOREHDL AFTERVLDL BeforeVLDL AfterSBP B SBP A DBP B DBP A
1 42 F 26.4 8 210 350 196 322 290 180 190 300 26 7.6 250 253 198 197 73 77 39 38 39 36 150 130 90 80
2 50 F 22.1 6.8 146 279 142 220 146 270 130 262 22 7 200 204 185 188 154 154 48 50 29 28 130 130 90 90
3 53 M 27 7 136 196 127 204 140 211 136 179 27 6.3 209 209 194 193 100 103 34 38 73 70 110 110 80 70
4 48 F 24 7 124 208 114 180 119 209 124 190 24 7 230 234 210 209 187 187 55 49 26 28 130 120 80 80
5 56 F 24.6 7.5 260 380 254 348 204 276 213 298 24.4 7 212 202 168 166 176 174 40 49 42 38 140 130 80 80
6 43 M 21.8 7 164 229 116 249 210 240 121 180 21.4 6.7 300 302 158 156 243 241 45 40 32 34 140 130 90 80
7 53 M 29.6 9 229 340 230 320 172 298 216 348 29.6 8.6 277 273 172 173 158 158 38 37 28 30 150 140 100 80
8 47 M 30 7.5 210 299 196 289 156 242 180 200 29 7 193 199 188 187 156 156 20 24 41 39 148 140 90 90
9 57 M 25.6 7.5 166 246 142 223 110 180 140 197 25.5 7.5 178 177 194 197 167 167 28 25 21 25 120 110 80 70
10 49 F 24 7 130 210 124 199 132 240 130 302 26 7.5 212 212 138 132 156 156 39 36 45 44 110 110 80 70
11 57 M 25.7 7.5 156 254 148 266 136 250 144 242 24.8 7.3 298 289 138 137 98 98 50 45 65 62 116 130 80 90
12 56 M 25 7.5 118 286 119 263 180 266 145 290 26 7.3 322 321 145 143 96 100 51 45 55 48 110 110 70 70
13 61 F 26.8 8 220 310 204 340 209 280 280 360 28 8 187 183 170 173 176 176 26 27 44 40 120 110 70 80
14 44 F 28.3 9 259 349 255 316 204 346 250 310 24 8.7 178 177 147 146 154 154 62 61 105 79 110 110 70 70
15 55 F 24.1 7.5 160 270 155 210 140 250 155 250 22 7 189 187 181 180 165 165 32 34 30 33 120 120 76 84
16 52 M 22.3 7 165 240 165 224 160 292 145 220 22 6.7 167 162 225 224 167 167 54 54 61 57 150 140 100 80
17 38 F 22.9 7 140 236 136 232 133 199 120 180 23 6.4 176 178 210 209 154 154 37 45 29 26 130 130 90 80
18 59 F 23 7 126 204 130 194 140 186 114 182 25 6.5 203 206 235 234 87 84 26 18 46 42 150 140 100 80
19 57 F 25 6.8 138 210 121 177 110 155 119 145 26 6 276 278 180 182 187 188 42 33 35 47 130 130 80 90
20 60 F 27.3 7.5 148 269 149 196 120 195 120 190 26 7 269 266 170 169 183 185 48 46 30 35 130 138 90 88
21 55 M 26 7.5 192 286 109 270 166 240 140 240 24 7.2 276 270 167 166 155 155 39 35 32 65 128 130 84 80
22 54 F 24 7 154 240 146 286 120 210 126 186 22 6.5 244 246 212 211 154 159 28 28 57 47 130 120 80 70
23 49 F 22.4 7 124 206 128 180 127 190 119 180 22 6.8 213 212 169 165 172 171 47 46 190 180 130 130 80 90
24 54 M 27.5 7.5 190 260 182 262 176 245 160 204 27 7.2 288 287 138 138 211 201 48 45 44 45 130 130 80 90
25 57 M 28 7.5 180 274 210 266 289 347 180 266 28 7.5 294 290 145 144 201 201 37 37 46 45 130 130 80 80
26 51 M 32.1 8.5 210 302 202 290 300 380 249 356 32 8.6 289 284 177 178 129 129 35 35 46 47 150 130 100 80
27 53 M 30.6 8.5 252 379 242 344 206 411 210 288 30 7.6 325 321 172 176 165 170 38 37 50 51 150 130 100 80
28 58 M 22 7 170 260 140 286 180 260 140 264 22 7 289 287 171 171 212 212 42 43 38 35 130 130 80 80
29 42 F 27 9.5 316 402 280 350 280 364 290 354 27 8.8 234 231 148 147 134 134 38 36 40 39 110 110 70 70
30 54 F 28.9 9 280 364 270 325 240 290 186 350 29 8 211 215 205 204 123 123 44 44 32 33 130 130 90 80
31 51 M 25 7 196 270 200 263 189 266 172 202 25 7 190 187 187 186 124 124 40 40 27 27 140 130 80 80
32 54 F 23.9 7 142 196 140 192 131 166 127 190 24 6.5 235 223 201 203 143 143 47 45 59 55 130 128 90 86
33 51 F 27 7.5 206 280 180 206 144 210 154 262 27 7.4 276 278 206 205 167 167 36 36 25 25 110 110 70 70
34 48 F 28.4 7.5 196 246 199 340 170 241 135 236 28 7.6 245 243 175 177 212 212 50 55 35 35 120 110 80 70
35 58 F 29.6 8 210 314 204 304 190 290 170 260 29.6 7 255 254 166 165 221 221 42 42 33 32 130 130 80 80
36 52 M 27.6 8.1 176 256 163 219 188 285 187 255 28 8 289 284 175 175 176 176 49 49 34 33 140 130 90 80
37 56 M 27.4 8 200 320 194 310 191 296 175 306 26 8 278 277 175 174 167 167 39 39 35 35 140 130 90 80
38 52 F 26.2 7.5 164 272 170 258 210 260 155 255 25 7.4 211 212 209 208 154 154 25 29 26 23 140 130 90 88
39 56 M 25 7.5 144 290 126 280 144 275 131 289 27 7.2 278 274 210 211 149 149 27 27 40 40 110 110 70 80
40 53 M 28.9 7 128 220 124 210 110 185 120 190 28.4 7 189 187 145 145 178 178 37 35 60 62 110 120 70 80
41 37 F 28 7.5 220 366 210 376 204 362 180 344 28 7.5 218 213 146 147 121 121 48 48 34 34 120 130 80 90
42 65 F 24.3 7 142 249 146 230 125 199 126 186 24 6.5 267 265 157 156 145 145 49 54 39 33 120 110 70 70
43 40 F 23 7.5 158 254 156 224 141 192 130 176 23 7.4 215 213 190 188 176 176 25 29 65 65 110 110 80 80
44 63 M 26.7 8.5 266 380 244 376 260 360 240 309 25.3 8 180 176 158 154 187 187 60 65 35 35 110 110 80 80
45 55 F 25.3 7 186 230 170 226 160 204 114 155 25 6.5 276 277 210 202 198 196 38 38 54 54 120 130 80 84
46 50 M 27.2 7.5 176 269 162 254 145 290 170 282 27 7.5 329 332 235 220 178 178 52 52 28 24 140 130 90 80
47 40 F 25 7.5 162 222 155 281 142 205 126 190 25 7 309 306 208 209 167 167 34 33 37 37 130 130 80 80
48 46 M 29.2 9.5 230 402 220 386 210 335 180 320 29 8.5 232 231 237 237 178 173 20 20 53 54 140 130 90 80
49 62 M 28.6 7.5 176 264 174 210 165 270 164 259 28 7.5 287 285 183 189 179 173 44 46 32 32 130 130 90 90
50 50 F 27.5 7.5 209 304 210 272 180 304 170 280 27.3 7 276 270 169 166 143 143 47 44 30 30 130 138 80 88
51 54 F 29.2 8.5 306 380 290 368 310 406 291 372 31 8.4 222 221 173 132 157 151 34 34 44 42 130 130 80 80
52 58 M 28.7 7.5 196 279 184 273 190 263 178 266 28 7.5 256 254 210 211 178 178 25 25 67 65 120 120 70 70
53 61 F 25.9 7.5 180 254 174 248 187 234 172 231 25 7.2 287 290 175 177 178 178 45 43 43 43 130 130 90 90
54 49 M 26 8.7 216 360 242 352 244 370 190 355 26.2 8.5 232 232 140 141 187 187 47 47 30 30 130 130 90 90
55 61 F 27.4 8.5 242 332 220 332 200 290 142 280 27 7.5 211 213 147 145 184 184 36 36 45 45 130 130 80 80
56 51 M 24.8 7 158 246 150 290 148 264 140 226 24 7 298 296 180 182 178 178 34 34 54 53 140 110 90 80
CONTROL GROUP
57 64 F 28.4 7 182 253 178 246 109 170 126 155 28 6.4 176 181 177 173 186 178 36 36 36 33 140 130 90 80
58 52 M 27 7.5 220 281 216 290 240 266 148 267 27 7 243 240 145 144 134 145 40 43 42 40 130 130 80 80
patient numberAGE GENDERBMI BeforeHbA1C beforeFBS0 PPBS0 FBS1 PPBS1 FBS2 PPBS2 FBS3 FBS3HBA1C ENDBMI ENDTC BF                      TC AF    TGL BF TGL AF LDL BF LDL AF HDL BF HDL AFVLDL BFVLDL AF SBP BF SBP AF DBP BF DBP AF
1 41 F 25.4 7.5 205 340 190 325 175 305 154 276 7 25 287 260 148 132 205 198 50 48 20 19 130 130 90 90
2 60 F 26.8 7 187 218 170 205 142 190 126 210 6.4 26.8 360 343 216 203 187 185 48 50 38 37 150 130 110 100
3 52 M 23.9 7.5 183 340 179 331 190 298 154 280 7 22.9 255 250 175 155 201 194 40 38 29 29 140 120 100 90
4 53 F 24 7 192 252 184 242 179 241 146 204 6.5 24 278 262 179 152 206 210 41 39 26 25 130 130 90 80
5 35 F 29.4 8 234 366 240 350 210 340 143 214 7.5 29.4 265 260 185 192 175 168 49 48 26 27 130 130 80 80
6 59 F 26 8 193 298 191 270 170 256 136 209 7.6 26 278 269 197 180 166 158 48 48 30 32 120 120 80 80
7 43 M 24 7 166 208 116 206 117 190 104 162 6 24 297 280 266 265 175 161 49 50 52 48 130 130 80 90
8 51 F 23.8 6.8 156 221 104 224 91 207 90 175 6.6 23.8 301 296 186 165 175 172 42 44 37 34 110 110 70 70
9 44 M 28 7 110 234 112 220 114 190 106 142 6.5 28 266 255 186 178 209 188 30 28 38 35 130 130 80 80
10 56 M 27.8 7.5 128 257 138 247 140 280 127 190 7 27.8 210 218 153 152 210 194 20 22 30 31 110 110 80 70
11 55 M 30.2 8 275 397 280 387 254 340 186 263 7.5 30.2 273 270 170 171 145 138 45 44 30 28 114 110 70 70
12 65 M 22.9 8.5 182 362 186 342 170 304 142 290 8 22.9 225 220 221 217 146 138 38 40 40 41 110 110 70 70
13 58 F 23.8 7 188 285 114 267 105 243 102 198 6.6 23.8 268 259 186 190 157 145 30 28 20 22 110 110 80 70
14 61 F 24 7.5 225 342 210 302 191 294 153 208 6.9 24 271 265 221 201 190 170 35 33 25 23 140 140 90 90
15 57 F 28 7.6 192 354 172 350 174 332 136 290 7.2 28 272 267 232 197 158 147 44 41 39 38 130 130 80 80
16 57 F 26.8 7 150 272 148 280 134 270 117 210 6.8 26.8 225 220 174 166 210 181 41 43 30 29 130 130 88 90
17 30 M 27 7.8 148 335 132 320 126 307 114 230 7.2 27 280 282 270 251 235 225 19 18 69 58 130 130 80 80
18 51 M 24 8 224 303 241 315 210 305 186 294 7.8 24 241 238 140 132 208 210 18 19 28 25 138 130 90 90
19 60 F 29.6 8 148 302 151 288 132 276 124 209 7 29.6 250 247 182 158 240 235 34 33 54 49 110 110 70 80
20 47 F 28.7 8.5 256 372 240 315 213 342 153 256 8.1 28.7 242 241 168 159 186 180 30 32 49 47 120 120 80 80
21 61 M 27 8 182 249 172 328 140 283 127 195 7 27 260 261 178 154 169 170 35 37 32 29 140 130 90 80
22 55 F 24 6.5 162 204 104 198 111 180 107 146 6.2 24 234 233 171 192 173 167 32 33 48 47 130 130 80 80
23 42 M 24.8 7 187 243 114 213 118 196 112 144 6.7 24.8 250 252 183 165 210 212 31 35 35 34 110 110 70 70
24 55 F 25 7 154 245 87 241 108 264 104 168 6.5 25 285 280 154 113 175 169 36 37 30 29 120 120 80 80
25 57 M 26.9 7.5 198 389 163 362 141 353 126 287 7 26.9 264 260 180 163 140 138 47 49 28 30 130 130 90 90
26 62 M 26 7.5 180 277 130 260 112 264 104 208 7.2 26 234 250 156 158 147 145 47 46 29 35 130 130 80 80
27 38 M 23 7.5 132 371 111 350 126 360 115 314 7 23 242 212 184 170 180 177 45 44 40 41 130 130 80 80
28 53 F 27.5 7 142 296 132 287 112 265 114 226 6.6 27.5 233 240 187 179 177 172 46 47 42 40 110 110 70 70
29 59 F 28.6 7.5 198 332 187 322 170 315 128 276 7 28.6 250 243 193 181 145 171 40 41 40 38 110 110 80 80
30 45 M 24.4 8 201 382 210 395 193 382 172 296 7.5 24.4 229 227 190 178 156 148 39 41 39 42 120 120 70 70
31 56 M 23.8 7 142 196 132 210 126 194 119 162 6.5 23.8 262 241 111 88 185 160 47 48 21 20 130 130 80 80
32 39 F 23.9 7.5 182 352 168 296 154 280 135 241 7 23.9 303 294 181 175 170 178 52 50 35 36 140 130 90 90
33 63 F 28.8 8 182 348 180 330 152 298 119 217 7 28.8 245 232 140 130 180 155 39 40 28 27 130 120 80 80
34 52 F 26.1 8.4 146 332 132 326 158 296 140 212 7.5 26.1 250 253 140 135 207 201 35 32 26 27 130 130 80 80
35 40 F 27.2 7.5 189 262 143 190 136 193 117 153 7.5 27.2 258 255 190 196 153 146 50 49 25 24 130 130 80 80
36 55 M 23 7.1 148 250 132 210 126 209 122 167 7 23 270 237 171 166 160 152 46 48 33 31 120 120 90 90
37 55 M 24.8 7.5 182 306 172 310 154 290 131 214 7 24.8 279 278 260 258 159 164 52 50 53 49 130 130 90 90
38 60 F 29 9.2 216 428 196 365 172 345 186 344 7 29 280 240 148 138 158 143 40 36 33 31 110 110 70 70
39 41 M 27.2 8.4 240 316 171 280 243 310 204 290 8.2 27.2 249 232 164 162 179 163 32 30 37 35 130 130 80 80
40 56 M 22.8 7 142 216 122 190 114 186 104 145 7.5 22.8 211 207 130 127 171 160 24 25 33 28 110 110 70 70
41 65 F 25 8 146 302 160 290 142 278 114 186 6.6 25 261 242 169 163 127 121 46 42 31 29 110 110 70 70
42 43 M 24.9 8 182 244 171 234 163 220 127 189 7.5 24.9 218 214 212 217 129 117 42 40 40 39 110 110 70 70
43 42 F 26 7.8 186 312 210 320 204 296 172 253 7 26 258 254 193 195 138 120 30 33 24 25 110 110 70 70
44 58 F 25.6 7 146 248 126 209 132 196 126 163 6.5 25.6 258 230 196 181 168 159 37 36 21 25 140 130 80 80
45 63 M 28.6 9 216 382 260 380 243 365 204 310 8.5 28.6 237 193 182 176 150 120 43 47 35 36 130 130 80 80
46 46 M 30 8.1 189 328 176 313 142 283 123 208 7.3 30 198 210 155 118 164 151 44 45 25 27 130 130 80 80
47 44 M 24 7.5 184 306 165 280 143 276 128 225 7 24 285 280 228 180 201 199 20 18 54 57 130 130 80 80
48 40 F 27 8.3 208 396 210 380 192 340 182 298 8.1 27 235 229 112 110 195 192 21 22 27 25 130 130 80 80
49 54 F 23 7 180 249 160 231 153 216 112 182 6.5 23 242 235 150 160 207 179 31 32 52 50 110 110 80 80
50 65 F 25.2 7.5 174 306 162 280 150 263 132 208 7 25.2 237 230 161 163 172 169 34 33 48 48 130 120 80 70
51 64 M 25 7 169 306 143 296 123 260 116 256 7 25 257 252 122 110 158 151 33 32 27 35 140 130 80 80
52 44 M 27.6 7.1 184 328 170 330 142 298 153 380 6.5 27.6 234 230 197 205 159 160 35 37 44 47 130 130 80 80
53 57 M 26 6.6 148 206 121 186 114 143 106 132 6 26 249 243 170 163 222 214 34 35 32 31 110 110 70 70
54 53 F 28.6 9 269 348 258 380 232 366 160 353 7.7 28.6 278 275 95 83 165 161 36 38 31 35 120 120 80 80
55 45 M 26 7 153 278 142 270 136 243 121 209 6.8 26 262 253 147 130 142 138 50 50 29 32 130 130 80 80
56 60 F 25.5 7.2 146 303 132 280 121 273 116 210 6.5 25.5 245 230 149 144 138 134 47 46 37 33 130 130 80 70
57 41 M 26 6.5 156 215 108 154 97 148 95 132 6.4 26 210 220 163 150 163 160 41 41 39 41 130 130 80 80
58 51 F 24.8 7 141 215 123 207 119 182 108 143 6.4 24.8 230 225 160 148 169 166 48 45 42 43 110 110 70 70
59 59 M 26.5 7.5 198 298 137 254 127 264 115 196 7 26.5 240 239 182 170 137 134 39 38 37 39 110 110 80 70
60 50 F 28.7 7 167 247 110 190 117 173 104 132 6.5 28.7 225 220 160 162 138 145 42 42 40 37 120 120 70 70
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